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ABSTRACT

THE RELEVANCE OF HEART RATE VARIABILITY CHANGES AFTER
HEART TRANSPLANTATION

by
Sheeba Arnold

Heart transplantation has become an established treatment for end-stage heart disease.
However, the shortage of donor organs is a major problem and long-term results are
limited by allograft rejection. Heart rate variability (HRV) has emerged as a popular noninvasive research tool in cardiology. Analysis of HRV is regarded as a valid technique to
assess the sympathovagal balance of the heart. The primary goal of this study was to
investigate the relevance of heart rate variability changes after heart transplantation. It
was found that spectral analysis of HRV is useful in detecting rejection episodes. Heart
transplantation leaves the donor heart denervated. Spectral analysis of HRV was found
appropriate to detect functional autonomous reinnervation. Extensive literature review
was done to validate the findings.
The paper is divided into two parts. The first part of the paper deals mainly with
the techniques and current status of heart transplantation. The second part, deals with the
relevance of heart rate variability and reinnervation after heart transplantation. The results
of the study suggest that heart rate variability analysis is a valuable tool in assessing the
cardiovascular status after heart transplantation.
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CHAPTER 1

INTRODUCTION

1.1 Objective
The objective of this thesis is to try to unravel the possible role of heart rate variability in
determining the incidence and functional significance of reinnervation after heart
transplantation, Cardiac transplantation, first introduced in 1967 1 , has emerged as the
most effective treatment for end-stage heart disease. Total cardiac denervation occurs
after transplantation. Although previously this state was thought to be permanent, recent
studies have provided evidence for reinnervation. However, the extent and time course of
reinnervation still remains a matter of debate. The primary aim of this study is to resolve
this controversy by using heart rate variability as a reflection of the relative activities of
sympathetic and parasympathetic systems.
This study focuses on the predictive power of heart rate variability to detect the
incidence of reinnervation, which is a measure of the extent of recovery after heart
transplantation. The history and current status of heart transplantation, and the insights
from the study of heart rate variability are reviewed in this study. An extensive literature
review was performed for finding the evidence for reinnervation and for assessing
relevance of heart rate variability changes after heart transplantation.
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1.2 Back Ground

The development of heart transplantation as a clinical tool for the treatment of heart
failure necessitated the contributions of scientists and clinicians whose work has taken
generations. The fields of vascular and thoracic surgery, immunology, pathology, medical
ethics, engineering, and medicine have contributed to the development and success of this
procedure. The contributions of people such as Alexis Carrel, Norman Shumway, and
Christian Barnard paved the way for the modern era of transplantation in which the major
obstacle to heart transplantation is no longer surgical mortality or rejection but donor
supply. In the following paragraphs the history, survival statistics, cost and rejection
issues of heart transplantation are summarized.
The following table gives the milestones in the development of clinical heart
transplantation'.
Table 1.1 Milestones in the Development of Clinical Heart Transplantation

1905

Vascular techniques

Carrel

1933

Recognition of graft rejection

Mann

1948

Cardiopulmonary bypass

Gibbon

1958

Myocardial preservation

Shumway

1960

Technique heart transplantation

Lower/Shumway

1967

First human heart transplantation

Barnard

1968

Definition of brain death

Harvard

11972

Modern immunosuppression

Borel

3

1.3 The History of Heart Transplantation

James D. Hardy attempted the first human heart transplantation at the University of
Mississippi Medical Center in January 1964. A 68-year-old man with ischemic
cardiovascular disease was the recipient patient 2 . As no human donor heart was available,
the heart of a chimpanzee was transplanted. The donor heart was preserved by the
retrograde gravity flow of cold, oxygenated blood through the coronary sinus. The
operative technique was that described by Lower, Stofer, and Shumway. The transplanted
heart functioned immediately, but the small donor heart could not handle the large venous
return of the recipient, and the patient died 1 hour after transplantation of the heart.
The first human-to-human heart transplantation was performed in 1967 in Groote
Shuur Hospital, South Africa. A 54-year-old man with intractable heart failure secondary
to ischemic heart disease was the recipient. The donor heart was that of a woman, an
accident victim, who died due to massive cerebral injuries. Using cardiopulmonary
bypass, arterial perfusion, hypothermia of the donor heart, and the surgical technique of
Lower and Shumway, the heart was implanted successfully in the waiting recipient. The
patient did well until day 18, when Pseudomonas pneumonia developed, Dr. Christian
Barnard was the surgeon who performed this first successful human-to-human heart
transplantation.
Denton Cooley performed the first successful heart transplantation on an infant at
the Texas Children's Hospital in Houston in 1984. The infant, an 8-month-old girl with
sub endocardial fibrosis, received the heart of a brain-dead 2-year-old infant.
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Adults up to 70 years old have been transplanted with good results. Patients with
transplants are surviving longer (the longest survivor received a transplant in January
1970, and died of non-cardiac causes in 1994.

1.4 Organization of Heart Transplantation in the U.S.

The procurement and distribution of organs for transplantation in the U.S. are the
contractual responsibility of the United Network for Organ Sharing (UNOS). UNOS was
established in 1972 as a voluntary association intended to serve the needs of the renal
transplant community. Because of its demonstrated commitment to organ procurement,
UNOS was awarded a federal contract in 1986 to establish and operate the Organ
Procurement and Transplantation Network. In 1987, UNOS was also awarded a separate
contract to maintain the scientific registry for organ transplantation. UNOS maintains a
national computerized list of patients waiting for kidney, heart, heart-lung, liver and
pancreas transplants, An "Organ Center" number allows 24-hr access to the computer
system by all transplant programs in the U.S. The Scientific Registry collects and
maintains data pertaining to patients waiting for transplants, donors, and recipients of
donated organs, donor-recipient matching and organ allocation and donor-recipient
histocompatibility.

1.5 Current Status of Heart Transplantation

The annual U.S. transplantation volume currently is limited by donor availability and has
been so limited since the mid-1980s. Conservative analysis of donor availability (by
review of causes of death listed on death certificates) indicates that approximately 5,200
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donor hearts (20.8 per million population) could be available annually, but this figure is
as high as 8,200 (32.9 per million population) if the criteria are only slightly liberalized 6 .
These estimates suggest that only 26% to 42% of available donor organs are utilized.
Intensification of efforts toward public education, effective legislation and improved
training of procurement coordinators are needed to reduce the number of potential donors
that remain unavailable for transplantation.

1.6 Survival Statistics

Survival statistics obtained from the general registry of International Society for Heart
and Lung Transplantation (ISHLT) as per April 1999 is shown in figures 1.1 and 1.2.

Figure 1.1 Overall adult heart survival (N=43,936)

The above statistics suggest that the number of people surviving decrease with the
number of years after transplantation. The time taken for the initial heart transplant
population to become half (half-life) was estimated as 8.8 years.

6

Figure 1.2 Survival by transplant era

The half-life for 1980-1985 was found to be 5.3 years and the half-life for 1986-1990 was
8.9 years. Even though the survival rate drops with time after transplantation, a
comparison of the different transplant era suggests that the survival rate has improved
from one transplant era to the other. This can be attributed to the advances in detection
techniques for rejection and other malignancies after transplantation.

1.7 Cost Issues

Total transplant charges vary according to several factors. For example, patients aged <=
18 years incurred higher charges than did patients aged > 18 years. Retransplant
procedures were more costly than primary grafts. Charges for patients who required an
artificial device for cardiac support were much higher than those who did not. Patients on
life support or in intensive care before transplantation incurred much higher postoperation charges than did patients who were hospitalized outside the intensive care unit
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or at home 6 . The range of heart transplantation procedure charges by category and
average length of hospital stay is shown in the following table.

Table 1.2 Range of Heart Transplantation Procedure Charges by Category and Average

Length of Hospital Stay
Category of Charges

Minimum

25 th

50th

75th

percentile

percentile

percentile

Maximum

Hospital charges

$8,173

$44,139

$62,463

$101,849

$1,290,033

Surgeon fees

2000

9000

10,000

12,500

40,391

Other professional fees

232

4,236

6,529

11,606

75,216

Donor organ

390

9,859

12,578

16,124

60,000

1.0

15.0

23.0

42.0

554.0

acquisition charges
Length of stay (days)

The data suggest that the average charge (50 th percentile) for transplantation is
about $91,570 (sum of the mean charges for hospital stay, donor organ acquisition,
surgeon fees and other professional fees) and the average length of stay is about 23 days.

CHAPTER 2

METHODS AND PROCEDURES

2.1 Introduction
Since the introduction of cardiac transplantation in 1967, the growth in the number of
transplant operations have been directly dependent on the identification and procurement
of cardiac allograft donors. The medical criteria for donor selection, the surgical
procedure, the recipient prioritization and donor allocation criteria, the means for
increasing donor supply, the complications and quality of life after transplantation and
some of the general statistics of heart transplantation will be discussed in this chapter.

2.2 Medical Criteria for Donor Selection
The initial step in donor procurement is the recognition and declaration of brain death of
the donor. It is the attending physician, not the members of the heart transplant or
procurement team, who diagnoses brain death. The clinical diagnosis of brain death
requires 1) that there be a loss of function of the entire brain and 2) that the loss of brain
function is irreversible.
The screening of potential cardiac donors is accomplished in three phases.
Primary screening is done by organ procurement specialists who work for the nonprofit
organ procurement agencies. Information pertinent to all organ donation is obtained
initially, including body size, ABO blood type, hepatitis B and human immunodeficiency
virus (HIV) sero-logic data, information on cause of death and clinical course and routine
laboratory data. Secondary screening is done by cardiac surgeons or cardiologists.
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relevant to cardiac donation includes determination of the circumstances leading to
severe brain injury, extent of other (especially thoracic) injuries, the extent of treatment
required to sustain an acceptable hemodynamic status, baseline electrocardiogram (ECG),
chest X-ray film, arterial blood gas analysis and echocardiogram. The purpose of this
secondary screen is to provide enough information to decide whether to implement the
tertiary screen, which is inspection of the heart by a "harvesting" surgeon.
In heart transplantation, an effort is made to match the muscle mass of the donor
heart to the expected cardiac output requirements of the recipient. A common practice is
to accept hearts from donors with a donor/recipient weight ratio of 0.8 or higher 3 . Donor
height is another variable that is considered because cardiac output often parallels body
height as well as weight. Because of a profound shortage of cardiac organ donors and
high pretransplantation mortality rates of patients listed for heart transplantation, it is
clear that donor-screening strategy should be liberal. Conversely, because primary graft
failure is almost always associated with death of the heart transplant recipient, the
screening strategy must identify hearts that will reliably support the circulation in the
immediate post transplantation period.

2.3 Surgical Procedure
There are two different surgical techniques for heart transplantation: standard surgical
techniques, which leaves most of the recipient atria intact and the bicaval technique in
which the whole recipient heart including the entire atrial junctions of both superior and
inferior venaecavae are removed and substituted with equivalent components of the
donor heart. Two different heart transplant methods employed are heterotopic and
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orthotopic. In heterotopic heart transplantation, the donor heart is connected either in a
parallel or non-parallel way to the recipient heart, which is left in place 4 . In orthotopic
heart transplantation, the recipient heart is removed and the donor heart replaces the
recipient heart (figure 2.1).

Figure 2.1 Schematic representations of experimental heart transplant models.
(Shumway and Shumway, Thoracic Transplantation, 1995.)

The operative technique employed for orthotopic heart transplantation" is
summarized in the following paragraphs.
The donor heart is removed from its sterile travel container and is placed in a
basin of cold saline solution. The aorta and pulmonary artery are separated. The
pulmonary veins are identified and connected first along their short axis and then along
their long axis, to form a single large posterior atrial cuff. After further adjustments,
which include the identification of mitral valve (the valve between the left atrium and left
ventricle), inferior vena cava, and superior vena cava, the donor heart is submerged in
cold saline solution until it is time for implantation.
For excising the recipient's native heart, the heart is exposed and cannulation is
carried out. The great vessels are divided just above the semilunar valves. The right
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atrium is incised along the atrioventricular groove. After the native heart has been
excised, the pericardial space is irrigated with cold saline solution. The prepared donor
heart is positioned to start the left atrial anastomosis, which is followed by right atrial
anastomosis. Once the atrial anastomoses are completed, the great vessel anastomoses are
done. First, the donor and recipient pulmonary arteries are sewn end-to-end and then the
donor and recipient aortas are sewn end-to-end, The different steps in the operative
procedure are given in the following figures.

Figure 2.2 The recipient's native heart is exposed and cannulation is carried out.
(Shumway and Shumway, Thoracic Transplantation, 1995.)
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Figure 2.3 The donor heart is prepared, The great vessels are separated (A). The left
atrial cuff is created by connecting the pulmonary veins (B) and (C). (Shumway and
Shumway, Thoracic Transplantation, 1995.)

Figure 2.4 The native heart has been excised. (Shumway and Shumway, Thoracic
Transplantation, 1995.)
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Figure 2.5 The recipient heart as it appears with all anastomoses completed. (Shumway
and Shumway, Thoracic Transplantation, 1995.)

2.4 Means of Increasing Donor Supply
Little information is available regarding donor-specific parameters that predict success or
failure after heart transplantation. Furthermore, with the increasing number of patients
awaiting heart transplantation, there is tremendous pressure to expand the donor pool by
stretching the margins of donor acceptability. To gain insight into donor-related and
donor-recipient interrelated predictors or death after transplantation, 1719 consecutive
primary transplantations performed at 27 institutions between Jan. 1, 1990, and June 30,
1992, were analyzed by Young et a1 3 , Mean follow-up of survivors was 13.9 months, and
actuarial survival was 85% at 1 year. There were 248 deaths during the period of follow
up. The three most common causes of death were infection (22%), acute rejection (18%),
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and early graft failure (18%). By multivariable analysis, risk factors for death included
younger recipient age, older recipient age, ventilator support at time of transplantation,
higher pulmonary vascular resistance, older donor age, smaller donor body surface area
(female donor heart placed into larger male patient), greater donor inotropic (inotropes
are administered to increase the force of contraction of the heart) support, donor diabetes
mellitus, longer ischemic time, diffuse donor heart wall motion abnormalities by
echocardiography, and, for pediatric donors, death from causes other than closed head
trauma. The overall 30-day mortality rate was 7% but increased to 11% when donor age
exceeded 50 years and was 12% when inotropic support exceeded 20μg/kg/min
dopamine plus dobutamine and 22% with diffuse echocardiographic wall motion
abnormalities. The 30-day mortality rate for older recipients were greater as compared to
younger recipients. The interaction of donor risk factors was such that the heart of a
smaller female donor given high-dose inotropes placed into a larger male recipient
produced a predicted 30-day mortality rate of 26% and the heart of a 25 year old male
donor given high dose inotropes with diffuse echocardiographic wall motion
abnormalities transplanted into a 50 year old male recipient led to a predicted 30 day
mortality rate of 17%. This analysis supports cautious extension of criteria for donor
acceptance but with an anticipated greater risk in the presence of diffuse
echocardiographic wall motion abnormalities and long anticipated ischemic time,
particularly in older donors given inotropic support.
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Table 2.1 Activity on Cadaveric Heart Waiting List in the Entire United States

1/1/1998 — 12/31/1998

1/1/1999 - 3/31/1999

Number Waiting At Start of Period

3,883

4,167

Number Added to the Waiting List

3,931

857

Number Transplanted

2,320

494

Number Died on Waiting List

773

185

Number Removed For Other Reasons

554

139

Number on Waiting List at end of period

4,167

4,206

(Source: ISHLT general registry')

2.5 Current Medical Indications for Heart Transplantation

The success of heart transplantation has resulted in a critical limitation of donor supply,
expanding waiting lists and increasing numbers of new transplant centers. The current
indications for transplantation have been described as end-stage heart disease including
heart failure, ischemic heart disease and arrhythmias 6 . Clinicians usually examine clinical
factors such as escalating medical requirements or frequent hospitalizations, and list
patients for heart transplantation when medical therapy seems doomed.
Ischemic heart disease and idiopathic dilated cardiomyopathy are the primary
underlying diseases leading to congestive heart failure severe enough to serve as
indications for heart transplantation in adults. Cardiomyopathies constitute a group of
diseases in which the dominant feature is the involvement of heart muscle itself. Ischemic
cardiomyopathy is a condition in which coronary artery disease results in severe
myocardial dysfunction. Patients with advanced valvular heart disease or congenital heart
disease are also suitable candidates at times. Heart transplantation has been considered in
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some centers to be a lower risk form of surgical intervention than high-risk
vascularization procedures or valve replacement and, hence, is recommended to some
patients rather than more conventional surgical interventions.

2.5.1 Recipient Priority for Heart Transplantation

The current means of recipient categorization in the U.S. includes an estimation of the
recipient's severity of illness and determination of ABO blood type, body size and length
of time on the waiting list 3 . Because of the expanding number of potential recipients, the
primary determinants of organ allocation have come to be severity of illness and time on
the waiting list 7 . The physically small adult recipient or recipients in AB or B blood
groups will usually be on a smaller waiting list, but donor availability is also limited for
these patients. Current prioritization systems include a local allocation system and a
national listing, both of which are supervised by UNOS 8 (United Network for Organ
Sharing).

2.5.2 Current Recipient Status Criteria of UNOS

Status I
Patients who require cardiac and/or pulmonary assistance with one or more of the
following devices:
1. Total artificial heart
2. Left and/or right ventricular assist systems
3. Intra-aortic balloon pump
4. Ventilator
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Or, patients meeting both of the following criteria:
1. Patient in an intensive care unit and
2. Patient requires inotropic agents to maintain adequate cardiac output
or, patients less than six months old.

Status II
All other waiting patients who do not meet the Status I criteria.

2.6 Current Allocation Criteria of LINOS
Hearts are allocated locally in the following sequence. For every thoracic donor, the
choice will be made locally whether to use the heart for a heart (without lung) transplant
for a Status 1 patient, or for a heart-lung combination transplant. If the heart is to be used
for a heart (without lung) transplant, the heart will be allocated first to local Status 1
patients according to length of time waiting. If the organ is not allocated to a Status 1
heart patient, then the heart will be allocated to a local patient awaiting a heart-lung
combination transplant who has a blood type that is identical to the donor, according to
length of time waiting. If the heart is not allocated to a local patient awaiting a heart-lung
combination transplant who have a blood type that is identical to the donor, then the heart
will be allocated to the local patients awaiting heart-lung combination transplantation
who have a blood type that is compatible with that of the donor, according to length of
time waiting. If the heart is not allocated to a Status 1 heart patient or a heart-lung patient,
then the heart is allocated to a local Status 2 (ABO identical) patient according to length
of time waiting.
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Local conflicts regarding allocation of hearts, lungs, heat-lung combinations,
locally unresolved inequities or conflicts that arise from prevailing OPO (Organ
Procurement Organization) boundaries or policies may be submitted to any interested
local member for review and adjudication to the UNOS Thoracic Organ Transplantation
Committee, Organ Procurement and Distribution Committee and Board of Directors 8 .The
distance of the recipient hospital from the donor hospital will also be used to prioritize
the recipient list for hearts, lungs and heart-lung combination not used by the local OPO.

2.7 Quality of Life After Heart Transplantation

Heart transplantation was previously considered an appropriate option only in patients
unlikely to survive 6 months, but patients today sometimes are considered candidates for
heart transplantation if they have 50% survival likelihood at 24 months. As more patients
are placed on waiting lists for heart transplantation and waiting times lengthen, the acuity
of illness of these patients may be lessening. Assessing quality of life variables after heart
transplantation, therefore, is important particularly when comparing the physiological
outcome after transplantation 9 . Some of the post transplant events that are indicative of
the quality of life after transplantation are given in the following tables. These data where
obtained from a follow up of patients in the US (from April 1994-December 1998) by
ISHLT.
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Table 2.2 Functional Status
Heart

1 Year

2 Year

3 Year

4 Year

Follow-up

Follow-up

Follow-up

Follow-tip

No.

%

No.

%

No.

%

No.

No Activity Limitations

5515

89.7

3779

92.2

2120

93.6

706

93.9

Performs with Assistance

525

8.5

278

6.8

131

5.8

40

5.3

Total Assistance

92

1.5

41

1.0

15

0.7

6

0.8

Table 2.3 Employment Status
Heart

1 Year

2 Year

3 Year

4 Year

Follow-up

Follow-up

Follow-up

Follow-up

No.

%

No.

%

No.

%

No.

Working Full Time

1494

27.6

1104

31

631

32

217

32.9

Working Part Time

447

8.2

308

8.6

157

8

47

7.1

Not Working

2589

47.8 ' 1465

41.1

763

38.8

234

35.6

Retired

892

16.5

19.2

418

21.2

161

24.4

684

Table 2.4 Re-hospitalization Post Transplantation
Heart:

1 Year

2 Year

3 Year

4 Year

Follow-up

Follow-up

Follow-up

Follow-up

No.

%

No.

%

No.

%

No.

%

3684

56.8

3180

75.9

1900

81.7

641

82.8

621

9.6

313

7.5

146

6.3

54

7.0

Hosp, Rejection

701

10.8

156

3.7

68

2.9

20

2.6

Hosp, Infection

1026

15.8

472

11.3

193

8.3

55

7A

Hosp, Rejection + Infection

454

7.0

69

1.6

19

0.8

4

0.5

No Hospitalization
Hosp., Not Rejection/Not
Infection
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Table 2.5 Malignancy - Post Heart Transplantation
1 Year Follow-up:

No: 96.1%
Yes: 3.9%

->

Lymph - 78 (31.8%)
Not Reported - 17 (6.9%)
Other - 66 (26.9%)
Skin - 84 (34.3%)

4 Year Follow-up:

No: 91.5%
Yes: 8.5%

>

Lymph - 8 (12.1%)
Not Reported - 2 (3.0%)
Other - 20 (30.3%)
Skin - 36 (54.5%)

The statistics indicate that the most of the heart transplant recipients could lead a normal
life after heart transplantation. However, the quality of life judgments are frequently
subjective and if a patient's premorbid quality of life is poor, it is unlikely to be
significantly changed by a heart transplant procedure. As compared to the total number of
patients undergoing heart transplantations, the number of reported cases of post
transplantation malignancy is relatively less. However, the statistics suggest that
malignancy increases with time after transplantation. This can be attributed to the
immunosuppressive agents administered to the transplant patients to suppress rejection.
Thus, transplant patients with malignancy can be at a higher risk of graft failure as
compared to transplant patients with no sign of malignancy,
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2.8 Complications After Heart Transplantation
Many of the early postoperative complications like primary graft failure can be avoided
by proper donor selection. Another complication, right ventricular failure secondary to
high pulmonary vascular resistance, can usually be avoided by careful screening of the
potential recipient before transplantation".
One of the leading causes of death in the first year after heart transplantation is
cardiac allograft rejection 12 . Some of the factors that are associated with an increased risk
of rejection are human leukocyte antigen (HLA) mismatch, female gender, younger
donor hearts, non-O blood types, etc. The main reason for the rejection of female hearts
may be the weight and height mismatch as compared to that of the recipient. The same
reason can be attributed to the rejection of small (younger) donor hearts

13

.

Since the introduction of the endomyocardial biopsy by Caves et al. in 1973, it
has been considered the reference standard for the detection of cardiac rejection and
assessment of the adequacy of antirejection therapy. Endomyocardial biopsy is an
invasive and expensive procedure, in which the clinician obtains a tissue sample from the
right or left ventricle using a bioptome via a transvenous or transarterial approach. Five
or six tissue samples (average size 1-4 mm) are often required to be certain of a given
histological finding since pronounced topographic variations may be found in the
myocardium 14 . There has been an intensive search for an accurate and reproducible
noninvasive method to detect acute rejection. Electrocardiography, echocardiography,
nuclear magnetic resonance imaging, nuclear scintigraphy 15 etc. are some of the
noninvasive methods to detect cardiac rejection. Heart rate variability (HRV) analysis,
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which will be discussed later in this paper, is another noninvasive tool to detect cardiac
rejection.

Table 2.6 Cause of Death Vs Timing of Death After Heart Transplantation

Cause of Death

1 Year

2 Years

3 Years

4 Years

5 Years

Cardiac allograft

4.6

19.3

20

24.7

25

Malignancy, Other

1.9

8.8

12

13.3

18.6

Lymphoma

0.9

4.1

4.5

3.4

2.9

Cytomegalovirus

1.5

1.5

0.6

0.5

--

Acute Rejection

13.3

12.7

8.8

5.7

2.2

Infection, Other

20.3

13.3

12.6

10.9

7.9

vasculopathy

(Source: ISHLT general registry')

The above data suggests that acute transplant rejection (which occurs as a result of the
body's resistance to foreign tissue), and infection is the main cause of death in early years
after transplantation. Immunosuppressive drugs are administered to suppress the immune
system to prevent rejection, but they also prevent the body from reacting to infection so
that even the mildest infection may be fatal. New immunosuppressive drugs are being
developed, and rejection is becoming less of a problem, but because of their toxicity
malignancy develops and it is one of the main causes of death in later years of
transplantation.
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2.9 General Statistics
Following are some of the general statistics of interest. These data were collected from
the sixteenth annual data report published by ISHLT 5 in April 1999.

Table 2.7 Number of Transplants and Centers
Organ

Number of Transplants

Number of Centers

Heart

48,541

304

Heart-Lung

2,510

124

Single Lung

5,347

153

Bilateral/Double Lung

3,751

140

The figures in the above gives the total accumulated number of transplants and transplant
centers as of April 1999. The graph given below shows the number of thoracic
procedures by year. Even though the plot shows an increase in the number of procedures
as compared to last decade, a recent drop has been found in the number. This can be
attributed to economic factors and scarcity of donor organs.

Figure 2.6 Number of thoracic procedures vs. number of procedures
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Table 2.8 Adult Heart Transplant Indications
Disease Category

Number

Percent

Cardiomyopathy

18,602

45.6

Coronary Artery Disease

18,599

45.6

Valvular Disease

1,398

3.4

Retransplant

891

2.2

Congenital Disease

646

1.6

Miscellaneous

646

1.6

The above data indicates that cardiomyopathy and coronary artery disease are the leading
causes for heart transplantation. A plot of the percent of cases for heart transplant
indications of cardiomyopathy and coronary artery disease is given below. Even though
there has been a decrease in the incidence of cardiomyopathy with time, percent cases for
coronary artery disease is found to increase. This may be due to the change in life style of
people as compared to the past decade.

Figure 2.7 Percent cases of heart transplant indication vs. percent of cases

Table 2.9 Age Distribution of Heart Transplantation
Age

Percent of Transplants

<1

2.44

1-5

1.82

6-10

1.17

11-17

3.17

18-34

9.77

35-49

27.46

50-64

47.31

>65

3.5

The above data suggests that the people in the age group of 35-65 constitute about 75%
of the total population of people undergoing heart transplantation. The plot given below
compares the percent of thoracic procedures in the east and west hemispheres. The
percent of double-lung transplants have been compared with that of heart-lung transplants
and has been found to increase with time. The west hemisphere holds a greater share of
transplantation as compared to the east hemisphere.

Figure 2.8 Heart-lung/Double-lung transplantation vs, percent of transplants

CHAPTER 3

FUTURE OF HEART TRANSPLANTATION

3.1 Introduction
Over the past decade heart transplantation has evolved from a rarely performed
experimental procedure to an accepted therapy for end-stage heart disease. Despite the
escalation in the number of procedures and progressive improvement in postoperative
outcome, two formidable obstacles, the issues of rejection and shortage of organ donors,
continue to challenge the success of heart transplantation 13 .
Contemporary immunosuppressive strategies" have reduced the incidence of
acute rejection but have severe limitations. These include lack of specificity, inability to
reduce the risk of cardiac allograft vasculopathy (the major factor limiting long-term
recipient survival), significant toxicity and an increased risk of opportunistic infections
and malignancy. The understanding of the immune response at increasingly fundamental
levels and the ability to combine data from in vitro assays of immune function with
information from in vivo models of organ transplantation and autoimmune disease have
enabled rapid advances in the discovery and development of new immunosuppressive
modalities.
Shortage of donor organs is another major problem facing heart transplantation.
Because the pool of potential candidates continues to expand while donor organs remain
critically scarce, the discrepancy between the number of patients who would benefit from
heart transplantation and the number of patients who actually receive a transplant
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continues to increase at an alarming rate. It is estimated that as many as 30% of patients
awaiting heart transplantation die before a suitable donor organ becomes available. The
severe shortage of donor organ emphasizes the crucial need for identifying alternatives to
allotransplantation. Potentials solutions include 1) xenotransplantation, 2) the application
of transformed skeletal muscle, and 3) mechanical assist and replacement devices".

3.2 Permanent Ventricular Assist Device Support Versus Cardiac Transplantation
Among heart transplant candidates, UNOS status II, O blood type, and weight >180 lb,
older age and preformed antibodies are negative factors for receipt of donor hearts. Of
patients transplanted, women and nonwhites have poorer outcomes 16 . Success with
wearable left ventricular assist device support (LVAS) suggests some of these patients
might be better served with an LVAS than with cardiac transplantation.
The Novacor N-100 wearable LVAS with biological valved conduits (Baxter
Healthcare/Novacor, Oakland, CA) and the Heartmate LVAS (Thermocardiosystems Inc,
Woburn, MA) are currently in use as electrically powered devices that fulfill all the
criteria for completely implantable systems except for their requirement for an
externalized drive system 16 . The N-100 LVAS system has the capacity to become a
completely implantable system, the proposed model of which is shown in figure 3.1. It
employs an integrated pump and drive unit, a compliance chamber that is to be housed in
the pleural space, an internalized battery system that can provide a backup energy source,
and a method of transmitting energy across the skin by inductive coupling from a primary
to a secondary coil.
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Figure 3.1 The proposed totally implantable Novacor LVAS. (Thoracic Transplantation;
Shumway and Shumway, 1995)

The strategy of transplantation in which patients may or may not receive a donor
heart is inadequate to serve the large number of potential candidates (figure 3.2). In 1995,
for instance, the mean waiting time for cardiac transplantation was over 200 days and
more than 40% of the patients waited more than 1 year for transplantation. Because only
about 4,000 new patients are listed for cardiac transplantation each year, about 28,00030,000 patients are apparently not considered viable candidates to be placed on the list.
Of those not placed on the list, it is possible that as many as half of them (13,000) would
be candidates for a permanent ventricular assist device (VAD). An important deterrent to
listing may be advanced age, because the estimate of 30,000 is made with an upper age
limit of 75 years, and the estimate of 60,000 is made with an upper age limit of 85 years.
It is also possible that current VAD technology using externalized drivelines might offer
a reasonable alternative to cardiac transplantation.
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Because LVAS devices could be made readily available without the need for a
waiting list, they might compete well with the strategy of heart transplantation. The most
obvious advantage of VAD systems over transplantation is their immediate availability.

Figure 3.2.Representation of severe heart failure patients that could benefit from a
permanent VAD on an annual basis. (Pennington et al., "Permanent Ventricular Assist
Device Support Versus Cardiac Transplantation," Ann Thorac Surg, 1999.)
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A positive psychological feature is the fact that LVAS insertion does not necessitate
removal of the natural heart, which might be able to temporarily support the circulation,
or recovers sufficiently to allow for device removal. The disadvantages include issues of
thromboembolism, requirements for platelet deaggregating drugs and issues of device
failure.
Thus LVAS may offer the opportunity to improve the quality of life in patients
who face a high mortality during their last six months of life. Although transplantation
will be important to maintain a small core of congestive heart failure patients, it is
apparent from many studies that unless some major changes occur in immunosuppressive
therapy or organ donor supply, LVAS devices hold the best promise for the future in
making any real impact on this huge public health problem.
3.3 Cardiac Retransplantation
Since the first report of cardiac retransplantation in 1977, sequential orthotopic
transplantation has become a frequent treatment for heart failure.
To evaluate the risk of cardiac retransplantation and to better establish selection
criteria, Michler et al reviewed the records of all patients who underwent
retransplantation at the Colombia-Presbyterian Medical Center. Of 431 patients who
underwent transplantation between February 1977 and March 1991, 408 underwent the
procedure in the era of cyclosporine-based immunosuppression. Thirteen of these 408
patients underwent retransplantation (including one patient who received a third graft).
Indications for the 14 retransplantations included transplant coronary artery disease
(n=8), rejection (n=5), and intraoperative graft failure (n=1). Immunosuppression and
follow-up protocol used in this cohort were similar to those in the primary transplantation

population. No significant differences were found (figure 3.2) in either actuarial survival
between primary transplant recipients and patients who underwent retransplantation or in
linearized rates of rejection and actuarial freedom from rejection between the two groups.
The results of this study indicated that the prognosis of patients undergoing cardiac
retransplantation is identified more than 30 days after initial transplantation.
Whether to use donor organs for retransplantation remains controversial. The
alternative of using ventricular assist devices should be considered whenever possible.
The clinician ultimately must balance a sense of therapeutic obligation to the transplant
recipient in question with the current scarcity of donor supply.

Figure 3.3. Percentage survival (top) for 395 and 14 patients who underwent primary
transplantation and retransplantation, respectively. Differences in percentage of survival
between these two groups were not statistically significant. Actuarial freedom from
rejection (bottom) for 295 and 12 patients who underwent primary transplantation and
retransplantation, respectively. Differences in actuarial freedom from rejection between
these two groups were not statistically significant. (Michler et al., "Clinical experience
with cardiac retransplantation", JAMA, 1998.)
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The one-year survival statistics of adult heart retransplanatation from the ISHLT
registry is given below.

Table 3.1 Adult Heart Retransplantation One-Year Survival

Inter-transplant

1-Year Patient Survival (%)

Interval (Months)

High

Low

Close ((High + Low)/2)

1

54.4

38.3

46.3

2

53.7

43.5

48.6

3-6

49.3

19.1

34.2

7-12

74.5

44.7

59.6

13-24

70.4

46.3

58.4

25-36

85.2

61.2

73.2

37-48

91.3

67.2

79.2

49-60

87.3

60.8

74

61-84

88.4

61.6

75

85+

85

69.7

77.3

(Source: ISHLT general registry')

The statistics show that there is a much better chance of survival if the inter-transplant
interval is greater than 6 months.

CHAPTER 4

HEART RATE VARIABILITY AS AN ASSESSMENT OF
CARDIOVASCULAR STATUS
4.1 Background
A complex signal that is commonly recorded in cardiovascular medicine is, the
electrocardiogram (ECG). Since the original description by William Einthoven in 1903,
the signal has traditionally been regarded as containing much significant information
about the heart. This information has, in the past, been derived from the interpretation of
short-term portions of the signal, i.e., one or two beats, or at most a short rhythm strip.
However, the ECG yields a complex signal that has additional information derivable
from longer time period analyses. The information in these longer segments of data forms
the basis of heart rate variability study.
In the following sections of this chapter, the neural control mechanisms of the
heart, the measurement techniques of heart rate variability, and its role in assessing
cardiovascular status, especially after heart transplantation, will be described.

4.2 Neural Control Mechanisms of the Heart
4.2.1Autonomic Nervous System
The autonomic nervous system (ANS) is that portion of the nervous system that controls
the visceral functions of the body. This system helps control arterial pressure,
gastrointestinal motility and secretion, urinary bladder emptying, sweating, body
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temperature, and many other activities, some of which are controlled almost entirely and
some only partially.
The ANS is activated mainly by centers located in the spinal cord, brain stem and
hypothalamus. Portions of the cerebral cortex and especially of the limbic system can
transmit impulses to the lower centers, and in this way influence autonomic control' s .
The autonomic signals are transmitted to the body through two major subdivisions
1. Sympathetic nervous system
2. Parasympathetic nervous system

Sympathetic Nervous System
Figure 4.1 shows the general organization of the sympathetic nervous system.

Figure 4.1 The Sympathetic Nervous System. Dashed lines represent postganglionic
fibers. (Basic Neuroscience: Anatomy and Physiology; Guyton, 1987.)
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The sympathetic nerves originate in the spinal cord between the spinal segments T1 and
L2 and pass from here into the sympathetic chain, then to the tissues and organs that are
stimulated by the sympathetic nerves. Each sympathetic pathway from the cord to the
stimulated tissue is composed of two neurons, a preganglionic neuron and a
postganglionic neuron. The cell body of the preganglionic neuron lies in the spinal cord
and its fiber passes through an anterior root of the cord into a spinal nerve. Immediately
after the spinal nerve leaves the spinal column the preganglionic sympathetic fibers leave
the nerve and pass through the white ramus into one of the ganglia of the sympathetic
chain. The postganglionic neuron originates either in one of the sympathetic chain
ganglia or in one of the outlying ganglia. From here the postganglionic fibers travel to
their destinations in the various organs. The sympathetic pathways originating in the
different segments of the spinal cord are not necessarily distributed to the same part of
the body as the spinal nerve fibers from the same segment. The sympathetic fibers from
T1 generally pass up the sympathetic chain into the head; from T2 into the neck; T3, T4,
T5 and T6 into the thorax; T7, T8, T9, T10 and T11 into the abdomen; T12, L1 and L2
into the legs' 8

.

Parasympathetic Nervous System
Parasympathetic fibers leave the central nervous system through several 10 out of the 12
cranial nerves and occasionally the first and fourth sacral nerves. About 75% of all
parasympathetic nerve fibers are in the vagus nerves (vagus nerve is the tenth cranial
nerve), passing to the entire thoracic and abdominal regions of the body. This is the
reason parasympathetic activity is also referred to as vagal activity. The vagus nerve
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supplies parasympathetic nerves to the heart, the lungs, the esophagus, the stomach, the
small intestine, the liver, the gall bladder, the pancreas and the upper portion of the
uterus. Parasympathetic fibers in the third cranial nerve flow to the pupillary sphincters
and ciliary muscles of the eye. Fibers from the seventh cranial nerve pass to the lacrimal,
nasal, and submandibular glands, and fibers from the ninth cranial nerve pass to the
parotid gland. The sacral parasympathetic fibers congregate and leave the sacral plexus
on each side of the cord and distribute their peripheral fibers to the descending colon,
rectum, bladder, and lower portions of the uterus. The sacral group of fibers also supplies
the external genitalia to control various sexual functions. The parasympathetic nervous
system is shown in figure 4.2.
The sympathetic and parasympathetic nerve endings secrete one of the two
synaptic transmitter substances, acetylcholine and norepinephrine. Those fibers that
secrete acetylcholine are called cholinergic and those that secrete norepinephrine are
called adrenergic. In general, the terminal nerve endings of the parasympathetic system
secrete acetylcholine and most of the sympathetic nerve endings secrete norepinephrine.
These hormones, in turn, act on the different organs to cause the respective
parasympathetic and sympathetic effects18

.

Sympathetic stimulation causes excitatory effects in some organs but inhibitory
effects in the others. Likewise, parasympathetic stimulation causes excitation in some
organs but inhibition in others. Also, when sympathetic stimulation excites a particular
organ, parasympathetic stimulation sometimes inhibits it, illustrating that the two systems
usually act reciprocally to each other.
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The sympathetic and parasympathetic systems are continually active, and the
basal rates of activity are known respectively as sympathetic tone or parasympathetic
tone. The value of the "basal" tone is that it allows a single nervous system to increase or
decrease the activity of the stimulated organ. The heart is the principal organ or driver of
the human body, which is responsible for supplying blood to the different regions of the
body, thus maintaining the blood pressure. The following sections attempt to explain the
relation between the heart and the autonomic nervous system and the latter's role in
influencing the performance of the former.

Figure 4.2 The Parasympathetic Nervous System (Basic Neuroscience: Anatomy and
Physiology; Guyton 1987.)
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A model suggested by Fleisher LA for cardiovascular regulation is shown in
figure 4.3. This model is a schematic representation of opposing feedback mechanisms
that, in addition to central integration, sub serves neural control of the cardiovascular
system. Baroreceptors and vagal afferents exert a negative feedback mechanism, whereas
sympathetic afferents exert a positive feedback mechanism.

Figure 4.3.Neural control mechanism of the cardiovascular system (Fleisher L.A., "Heart
rate variability as an assessment of cardiovascular status," Journal of Cardiothoracic and
Vascular Anesthesia, 1996.)
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4.2.2 Conductive System of the Heart
Figure 4.4 shows the specialized excitatory cells and conductive system of the heart that
controls the cardiac contractions 19 .

Figure 4.4 The SA node and the Purkinje system of the heart, showing also the AV node,
the atrial internodal pathways and the ventricular bundle branches. (Basic Neuroscience:
Anatomy and Physiology; Guyton 1987.)

The following are the main components that have a role to play in the excitation and
conduction mechanism occurring in the heart:

1. The S-A node, which is a small, ellipsoid strip of specialized cells, located in the
anterosuperior wall of the right atrium. The S-A node is the portion of the heart's
specialized conducting system that displays self-excitation property at the highest
frequency. The normal rhythmic impulse that paces the heart is generated here.

2. The internodal pathways that conduct the impulse from the S-A node to the A-V node
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3. The A V node, located in the septal wall of the right atrium that delays the
-

transmission of the cardiac impulse from the atria into the ventricles before
ventricular contraction begins, thereby facilitating a coordinated and smooth pumping
action,
4. The A-V bundle, which conducts the impulse from the atria into the ventricles, and

5. The left and right bundles of Purkinje fibers, which conduct the cardiac impulse to all
parts of the ventricles,

4.2.3 Autonomic Nervous System and the Heart
The heart is supplied with both sympathetic and parasympathetic nerves as shown in
figure 4.5.

Figure 4.5 The Cardiac Nerves. (Basic Neuroscience: Anatomy and Physiology; Guyton
1987.)

41

The parasympathetic nerves are distributed mainly to the S-A and A-V nodes, to a lesser
extend to the muscle of the two atria, and even less to the ventricular muscle. The
sympathetic nerves, on the other hand, are distributed to all parts of the heart, with a
strong representation to the ventricular muscle as well as to all other areas.

Autonomic Nervous System and Pumping Efficiency of the Heart

The sympathetic and parasympathetic nerves have a strong influence on the pumping
efficiency of the heart. The amount of blood pumped by the heart each minute, i.e. the
cardiac output (-5 liters per minute) can often be increased more than 200% by
sympathetic stimulation.

Effect of Sympathetic Excitation

Strong sympathetic stimulation can increase the heart rate in the humans to as high as 200
to 250 beats/min in young people. Sympathetic stimulation can also increase the force
with which the heart muscle contracts, thereby increasing the volume of blood pumped as
well as increasing the ejection pressure. During vigorous exercise can even increase
sevenfold.

Effect of Vagal Excitation

Strong vagal stimulation of the heart can even stop the heartbeat for a few seconds.
Strong parasympathetic stimulation, in addition, can decrease the strength of heart
contraction by as much as 20 to 30%. The relatively modest decrease in cardiac

42

contractility is primarily because the vagal fibers are distributed mainly to the atria and
not much to the ventricles, where the power contraction of the heart occurs1 9 .
The effect of the sympathetic or parasympathetic stimulation on the cardiac
output can be gauged from the cardiac function curve shown in figure 4.5.

Figure 4.6 Effect on the cardiac output curve of different degrees of sympathetic and
parasympathetic stimulation. (Textbook of Medical Physiology; Guyton; Eighth edition)

The curves demonstrate that at any given right atrial pressure, the cardiac output
increases with increasing sympathetic stimulation and decreases with increasing
parasympathetic stimulation. But it is also to be noted that nerve stimulation affects both
the contraction strength of the heart as well as the heart rate, both of which play a role in
determining the cardiac output. The following section examines the influence of ANS on
heart rhythmicity and conduction,
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Effect of ANS on the Heart Rhythmicity and Conduction
The parasympathetic nerves are distributed mainly to the SA node and AV node. Its
presence in the muscles of the atria, as mentioned before, is less and to the ventricular
muscles less yet. The sympathetic nerves on the other hand are distributed to all parts of
the heart with a strong presence in the ventricular muscles.
Stimulation of the parasympathetic fibers to the heart results in the hormone
acetylcholine being released at the vagal endings. This hormone has two major effects on
the heart. First, it decreases the rhythm rate of the sinus node, and second it decreases the
excitability of the A-V junctional fibers between the atrial musculature and the A-V node,
thereby slowing the transmission of the cardiac impulse into the ventricles. This results in
slowing down the heart rate.
Stimulation of the sympathetic nerves releases the hormone norepinephrine. This
hormone, firstly, increases the rate of sinus nodal discharge. Secondly, it increases the
rate of conduction as well as the level of excitability in all portions of the heart. Thirdly,
as described earlier, it greatly increases the force of contraction of all the cardiac
musculature, both atrial and ventricular. In short, sympathetic stimulation increases both
the heart rate and the strength of contraction.
Systemic blood vessels are one of the other organs affected by the ANS. Most
blood vessels, especially those of the abdominal viscera and the skin of the limbs, are
constricted by sympathetic stimulation. Parasympathetic stimulation generally has no
effect on blood vessels but does dilate vessels in certain restricted areas. Since the
sympathetic stimulation can increase both, the propulsion by the heart and resistance to
the flow of blood through the blood vessels, the arterial pressure can increase greatly in
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response to sympathetic stimulation. On the other hand, parasympathetic stimulation
decreases the pumping by the heart, which in turn lowers the arterial pressure by a
moderate amount.
Due to the role played by the ANS in regulating all major organs in the body,
diagnostic tests to assess the integrity of the ANS and its modulating effects on the heart
have been developed. The basic objectives of such tests is to subject the ANS to a known
stressor that activates a reflex and measure the response of the end organ, namely the
heart. The heart response to such stresses as a change of position from supine to standing,
deep breathing, valsalva (blowing into a sphygmomanometer to maintain a pressure of
about 40 mm of Hg in it, for 10-15 seconds), emotional stress, and lower body negative
pressure has emerged as an index of autonomic control.

4.3 Heart Rate Variability
Resting heart, rate (HR) varies widely in different individuals. During various
physiological stresses, particularly exercise, it can even increase by threefold. The
average value of heart rate in normal individuals in the resting state is around 72
beats/min. This value varies in the range of 60-90 beats/min in a day. During exercise this
value could reach as high as 220 beats/min. Age is a limitation to exercise capacity. By
heart rate variability is meant the continuous changes occurring in the beat-to-beat
interval. Heart rate variability (HRV) is mainly affected by respiration and by blood
pressure.
Respiration affects the heart rate through the parasympathetic nervous system
only
20

The clinical relevance of HRV was first appreciated in 1965 when Hon and Lee
noted that fetal distress was preceded by alterations in interbeat intervals. During the
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1970's Ewing et al devised a number of simple bedside tests of short-term RR differences
to detect autonomic neuropathy in diabetic patients. Wolf et al first showed the
association of higher risk of post infarction mortality with reduced HRV in 1977. In
1981, Akselrod et al, introduced power spectral analysis of heart rate fluctuations to
quantitatively evaluate beat-to-beat cardiovascular control 21 .
The clinical importance of HRV became appreciated in the late 1980s, when it
was confirmed that HRV was a strong and independent predictor of mortality after an
acute myocardial infarction. With the availability of digital, high frequency, 24-hour,
multichannel ECG recorders, HRV has the potential to provide additional valuable
insight into physiological and pathological conditions and to enhance risk
stratification22,23 . The following chapters will investigate the role of HRV analysis in
predicting the extent of reinnervation after cardiac transplantation.
Heart rate is dependent, among other things, on the physical fitness, mental stage
and age. In addition, even in the absence of external perturbations, the normal heartbeat is
not characterized by clockwork regularity. Periodic changes in HR occur at a high
frequency due to the influence of respiration throughout the day and night. In addition
very slow circadian changes occur that are mediated by neural and hormonal influences
and various uncertain influences. Both the basic heart rate and its modulation are
primarily determined by alterations in autonomic tone. As was discussed before,
increased parasympathetic or vagal tone slows the HR, and increased sympathetic tone
increases the HR. It has been shown that normal aging results in a reduction in autonomic
control of the heart.
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Changes in HR (heart rate variability) may be measured by a number of
techniques, and since changes in HR are autonomically mediated, these measurements,
reflect autonomic tone. The techniques used for analysis involve both the frequency
domain and time domain".

4.3.1 Time Domain Methods
In these methods, either the heart rate at any point in time or the intervals between
successful normal complexes are determined. In a continuous ECG record, each QRS
complex is detected, and the normal-to-normal intervals (NN) intervals (that is, all
intervals between adjacent QRS complexes resulting from sinus node depolarization) or
the instantaneous heart rate is determined. Simple time domain variables that can be
calculated include the mean NN interval, the mean heart rate, the difference between the
longest and the shortest NN interval, the difference between night and day heart rate, and
so forth".

Table 4.1 Selected Time Domain Measures of HRV
Variable
SDNN
SDANN

Units
ms
ms

RMSSD

ms

SDNN
index
SDSD
NN50
count
PNN50
HRV
triangular
index

ms
ms

%

Description
Standard deviation of all NN intervals
Standard deviation of the averages of NN intervals in all 5-minute
segments of the entire recording
The square root of the mean of the sum of squares of differences
between adjacent NN intervals
Mean of the standard deviations of all NN intervals for all
5-minute segments of the entire recording
Standard deviation of differences between adjacent NN intervals
Number of pairs of adjacent NN intervals differing by more than
50 ms in the entire recording
NN50 count divided by the total number of all NN intervals
Total number of all NN intervals divided by the height of the
histogram of all NN intervals measures on a discrete scale with
bins of 7.8125 ms (1/128 seconds)
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4.3.2 Frequency Domain Methods
Influences of HRV occur at different periodic oscillations. Frequency domain analysis is
a mathematical tool to determine each of these oscillations on the overall heart rate
pattern. The underlying principle is that any time series is made up of the combination of
much simpler oscillations with differing amplitudes and phases. Fourier transformation
algorithms and autoregressive (AR) techniques are used to separate these components.
The primary difference between the two methods is that the Fourier transformation
contains all of the information of the original time series, whereas the autoregressive
technique uses modeling to depict a specific time series and is therefore less dependent
on underlying periodicity 24 . The modeling results in smooth curves as an output, which
allows better distinguishing of the different peaks.
In order to calculate the Fast Fourier Transformation (FFT), RR intervals must be
converted to a series of evenly spaced data points, which may be expressed as either RR
intervals or as heart rate. This process is called interpolation. The influence of any ectopic
beats must also be removed. Even rare ectopic beats can lead to significant changes in the
power spectra, so periods surrounding ectopy are usually replaced with normal interval
data. Data must also be stationary over the analysis period; therefore short periods from 2
to 5 minutes are usually analyzed.
If the model order is not too low, AR technique has better resolution than the FFT
technique. Figure 4.7 shows the statistical stability (i.e., less noise) in the curve
determined by AR estimation. If the model order is too low, there is too much noise and
the resolution is not very good. Conversely, if the model order is too high, there is too
much smoothing and the signals from the data are not easily detectable20.
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Figure 4.7 Power spectral density curves of the AR technique and the FFT technique
using 478 segments of heart period. (Cowan M.J., "Measurement of heart rate
variability," Western Journal of Nursing Research, 1995.)

The following are the steps involved in interpolation: first the point process
signal is derived from the ECG by detecting the R waves. The point process signal
consists of an impulse at every time instant that an R wave occurs. The samples between
each impulse are then filled in with a constant value corresponding to the duration of the
interval preceding that R wave. This is referred to as backward step interpolation. The
samples may also be filled in with a constant equal to the inverse of the duration of the
previous inter-beat-interval (DM). Figure 4.8 shows the steps in deriving the backward
step interpolated IBI signal.
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Figure 4.8 Backward step interpolation of the IBI (Shin S., et al., "Assessment of
autonomic regulation by the method of complex demodulation," IEEE Transactions in
Biomedical Engineering, 1983.)

Power spectral analysis of the heart rate has emerged as a powerful technique for
the study of the ANS as it provides a window through which neurocardiac function can
be assessed noninvasively. The power spectral analysis process transforms a signal from
the time domain to the frequency domain. The power spectrum of either HR or BP
variability yields three major bands. A low frequency peak that appears within the
spectral band ranging from 0.04 Hz to 0.15 Hz is associated with baroreceptor-mediated
blood pressure control. A high frequency peak in the range 0.15 to 0.4 Hz is strongly
correlated with respiratory sinus arrhythmia. The major activity in this band is due to
respiration and a predominant peak usually occurs at the respiration frequency. A very
low frequency peak (VLF) between 0.0033 and 0.04 Hz has been linked with vasomotor
control and/or temperature control. A fourth band called ultra low frequency (ULF) is
also found between 1.15x 10 -5 and 0.0033. Measurement of ULF is based on the 24-hour
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recording and reflects circadian rhythms and contains most of the variance in the 24-hour
spectrum.
The high frequency band (HF) has been linked with parasympathetic activity; the
greater the area under the HF peak, the more active is the parasympathetic system. The
low frequency band (LF) is related to both sympathetic and parasympathetic activities.
Selected Frequency Domain Measures of HRV in both short-term and long-term
recordings are given in the following tables 24 . The long-term recordings include a ULF
component. This is due to the circadian rhythm over the 24-hour period. In order to avoid
the problem of "stationarity", spectral analysis performed on the entire 24-hour period as
well as spectral results obtained from shorter segments are averaged over the entire 24hour period. This provides averages of the modulations attributable to the LF and HF
components. Such averages obscure the detailed information of the autonomic
modulation of RR intervals that is available in shorter recordings. Thus the components
of HRV provide measurement of the degree of autonomic modulations rather than the
level of autonomic tone 24 .

Table 4.2 Analysis of Short-term Recordings (5 min)
Variable

Units

Description

5-min total
power
VLF
LF
LF norm

ms2

HF
HF norm

ms2
nu

The variance of normal to normal (NN)
intervals over the temporal segment
Power in VLF range
Power in LF range
HF power in normalized units (nu)
HF/(total power-VLF)*100
Power in HF range
HF power in normalized units (nu)
HF/(total power-VLF)*100
,
2
Ratio LF [ms - VHF [ms-

LF/HF

ms 2
ms 2
nu

Frequency
Range
,--, <=0.4 Hz
<=0.04 Hz
0.04-0.15 Hz

0.15-0.4 Hz
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Table 4.3 Analysis of Entire 24 Hours
Variable

Units

Description

Total power

ms 2

ULF
VLF
LF
HF

ms 2
ms 2
ms 2
ms 2

The variance of normal to normal (NN)
intervals over the temporal segment
Power in ULF range
Power in VLF range
Power in LF range
Power in HF range
Slope of the linear interpolation of the
spectrum in a log-log scale

Frequency
Range
=<=0.4 Hz
<=0.003 Hz
0.003-0.04 Hz
0.04-0.15 Hz
0.15-0.4 Hz
- - --<=0.04 Hz

The time domain measures correlate strongly with many of the frequency domain
measures. HF correlates with RMSSD and pNN50. LF and VLF correlate with SDNN
index. ULF correlates with SDNN and SDANN. (Refer to table 4.1).
The following is a typical power spectrum of the heart rate variability 25 .

Figure 4.9 A typical power spectrum of the heart rate variability (Kamath M. and Fallen
E., "Power spectral analysis of heart rate variability," Crit. Rev. in Biomed. Eng., 1993.)
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4.3.3 Standard Measurement of HRV
Standardization is needed particularly in studies investigating the physiological and
clinical potential of HRV. To standardize physiological and clinical studies, both shortterm and long-term recordings are used. Frequency domain methods should be preferred
to time domain methods when short-term recordings are investigated. The time domain
methods are ideal for the analysis of long-term recordings.
Equipment designed to analyze HRV in long-term recordings should implement
time domain methods, including all four standard measurements (SDNN, SDANN,
RMSSD, and HRV triangular index). In addition to other options, the frequency analysis
should be performed in 5-minute segments (using the same analysis as with the precision
of 5-minute ECGs). When spectral analysis of the total nominal 24-hour record is
performed to compute the whole range of HF, LF, VLF, and ULF components, the
analysis should be performed with a similar precision of periodogram sampling as
suggested for the short-term analysis (with sampling frequency > twice the maximum
frequency of the signal).
To ensure the quality of different equipment involved in HRV analysis and to find
an appropriate balance between the precision essential to research and clinical studies and
the cost of the equipment required, independent testing of all equipment is needed 24 .
Because the potential errors of the HRV assessment include inaccuracies in the
identification of QRS complexes, the testing should include all the recording, replay, and
analysis phases.
The strategy of obtaining the data for the HRV analysis should use the design
outlined in figure 4.10.
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Figure 4.10 Flow chart summarizing individual steps used when recording and
processing the ECG signal in order to obtain data for HRV analysis. (Camm A.J., et al.
"Standards of heart rate variability," Circulation, 1996.)
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4.4 Clinical Relevance of Heart Rate Variability
In recent years, a growing number of reports have shown that the analysis of HRV is a
valid non-invasive tool capable of providing adequate information on autonomic
modulation of the sinus node in normal subjects and in patients with a variety of cardiac
and non-cardiac diseases 26 . The basic assumption behind this methodology is that
sympathetic and vagal neural activities directed to the heart are largely responsible for the
beat-to-beat fluctuations that also characterize heart period during resting controlled
conditions 27 . Assessment of HRV may therefore furnish an indirect measure of
sympathovagal interaction, which is one of the major determinants of the functional
properties of the heart. To validate this hypothesis, an extensive literature search was
performed, the results of which are discussed in the following paragraphs.
Power spectral analysis of heart rate has been used to examine the period before
the onset of myocardial ischemia. Bigger et a1 28 studied 14 patients enrolled in the
Mulicenter Study of Silent Myocardial Ischemia. They found that both the LF and HF
power decreased to half their control values during segments with ischemic episodes28 .
The ratio of LF/HF power did not change significantly during segments of ischemia. The
authors suggest that the pattern of change suggested a predominant decrease in
parasympathetic activity during ischemic episodes.
Vardas et al studied 15 patients with three-vessel coronary artery disease. They
compared spectral power at five intervals before the start of ischemia and at the end of
ischemia. They observed a significant decrease in HF power and an increase in the
LF/HF power between the initial intervals versus the start of ischemia.
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Beattie and Buckley studied episodes of nonhemodynamically related myocardial
ischemia after noncardiac surgery. They observed a decrease in HF power before the
onset of ischemia, suggesting a predominance of sympathetic tone over parasympathetic
tone.
Both time and frequency domain measures of HRV are reduced in patients with
congestive heart failure compared with normal subjects. The degree to which HRV is
reduced depends on the severity of the disease. Saul et al studied patients with severe
congestive heart failure. They observed only VLF components, usually centered around
0.015 Hz. They suggest that the preservation of the VLF component is due to 60- to 80second oscillations of heart rate associated with a similar pattern in respiratory activity.
This is an indicator of lack of autonomic control, followed by a diminished vagal activity
during congestive heart failure.
Decreased HRV is associated with increase in mortality 29 . Kleiger et al. (1987)
reported that the relative risk of death was 5.3 times higher in 850 patients followed 31
months after myocardial infarction with a decreased HRV in time domain (standard
deviation of normal beat intervals (SDNN) <50 milliseconds) than that of the group with
an HRV>100 milliseconds (figure 4.11). This definitive finding has favored wide use of
this methodology in patients with diseases like myocardial infarction, congestive heart
failure and hypertension. From a general point of view, HRV can be used in clinical
practice to estimate 1) the integrity of cardiac autonomic innervation, 2) the physiological
status of cardiac autonomic activity and 3) the vulnerability to various cardiac
arrhythmias resulting from autonomic imbalance.
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Figure 4.11 Cumulative survival follow-up as a function of heart rate variability
(Fleisher L.A., "Heart Rate Variability as an Assessment of Cardiovascular Status,"
Journal of Cardio thoracic and Vascular Anesthesia, 1996.)

The denervated hearts of patients after cardiac transplantation provide a unique
model for understanding cardiac autonomic innervation. As a result of the lack of
innervation, there is a greatly reduced total spectral power and there are no distinct
spectral peaks of HRV in the hearts of these patients. After an interval of more than a
year, predominantly low-frequency spectral components might appear that suggest
possible cardiac reinnervation. The most important observation for clinical practice
seems to be the potential of HRV to detect rejection episodes in the transplanted heart.
Reinnervation and HRV after heart transplantation are discussed in detail in the next two
chapters.

CHAPTER 5

HEART RATE VARIABILITY AFTER HEART TRANSPLANTATION

5.1 Introduction
Analysis of heart rate variability is regarded as a valid technique to assess non-invasively
the sympathovagal balance of the heart. Frequency domain analysis of heart rate
fluctuations identifies the relative influence of the two neural limbs (sympathetic and
parasympathetic) that regulate heart rhythm. Mortara et al conducted a study to test the
hypothesis that power spectrum analysis of heart rate variability in congestive heart
failure may identify patients with a more pronounced sympathovagal imbalance and who,
as a consequence, could have a poorer prognosis 30 . Power spectral estimates of recipient
sinus rhythm fluctuations were used to assess the sympathetic and parasympathetic
modulation of the heart after hemodynamic function had been improved by heart
transplantation. The methods, results, and conclusions of the study are discussed in the
following paragraphs.
Spectral indices of heart rate variability were assessed in 30 patients in severe
congestive heart failure (CHF) and in 13 patients after orthotopic heart transplantation 30 .
A group of 15 age-matched subjects served as controls. Heart rate variability was
assessed by standard ECG in patients in heart failure and by esophageal ECG in patients
after heart transplantation. The subjects were in a supine position while recordings were
taken. Compared with controls, the mean RR interval and total power of HRV were
reduced in heart failure. The 30 CHF patients showed two different patterns of heart rate
variability: in 14 no power was detected in the low frequency band (LF) and total power
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was mainly concentrated in the high frequency band (HF), whereas in the remaining 16
patients power in the LF band was increased and power in HF band was reduced
compared with the controls. Patients with undetectable LF had a lower mean RR interval
and total power, higher concentration of plasma noradrenaline, and worse clinical status
and prognosis (4 deaths Vs no deaths at 6 month follow up) than patients with a dominant
LF band. In the post-transplant group, HRV of the RR interval sequences of the donor
heart and the PP interval sequences of the recipient atrium were analyzed. Both the mean
PP interval of the remnant atrium and total power resembled results in the patients with
heart failure; in 7 of the 13 post-transplant patients no power was detectable in the LF
band: when both HF and LF power were present the results resembled those in the 16
patients in heart failure. The rest of the transplant patients had a well-defined low
frequency peak though it was of very low amplitude.
These data suggest that in more advanced stages of congestive heart failure,
power spectral analysis of heart rate variability allows identification of a subgroup of
patients with higher sympathetic activation and poorer clinical status who are at major
risk of adverse events. In the short term after cardiac transplantation, the spectral profile
of the rhythm variability of the remnant atrium was not improved, suggesting that
parasympathetic withdrawal and sympathetic hyperactivity persist, despite the restoration
of ventricular function. The lack of heart rate variability short term after transplantation is
an indicator of autonomic imbalance, which usually improves with time after
transplantation.
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5.2 Heart Rate Reactivity Throughout the First Year after Heart Transplantation
Heart rate reactivity (the capacity of the heart to react to mental stress) is substantially
blunted early after heart transplantation, suggesting that the loss of neural modulation,
limits the cardiovascular response to mental stress. Heart rate reactivity could be used as
a measure of reinnervation because better heart rate reactivity is an indication of better
neural control of the heart. Shapiro et al tested whether reactivity to mental stress
recovers during the first year after heart transplantation

31

. Hemodynamic and respiratory

responses to mental arithmetic challenge were studied in 20 heart transplant recipients 3,
6 and 12 months after surgery. A normal comparison group was studied at equivalent
intervals. Heart rate reactivity to mental arithmetic was significantly reduced in the
cardiac transplant group compared to the normal subjects. This effect persisted up to 1
year after transplantation. Heart period variability in the heart transplant recipients was
minimal in all three test sessions. The findings suggest that no functional reinnervation or
other compensatory adaptation occurs up to 1 year after heart transplantation.

5.3 Long term Follow up of HRV in Patients After Heart Transplantation
-

To evaluate HRV within 5 years of follow-up Folino et al studied 20 patients who
underwent orthotopic heart transplantation 68 . Six measurements were taken: one in the
first 3 weeks after transplantation, and the others once annually, for 5 years. Twenty
healthy subjects constituted the control group. HRV increased in the first 3 years of
follow-up. In the following years this trend slackened and values did not reach a
statistically significant difference, suggesting that variations in HRV improved
significantly during the first 3 years after transplantation as compared to later years. The
mean standard deviation of HRV was invariably greater in the control group. These
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findings show that sinus rhythm variability in the denervated heart progressively
increased over 5 years of follow-up. The factors associated with this increase were
increase in beta-adrenergic receptor density or affinity as well as sympathetic
reinnervation.

5.4 Reinnervation of the Transplanted Heart
After heart transplantation the heart is denervated, so in principle, no heart rate variability
should be present. However, accurate recordings with direct computer acquisition of
ECG with increased time resolution (1-2 msec) demonstrate that the RR interval is not
fixed, but fluctuates rhythmically, synchronous and coherent with the respiratory signal.
The origin of this fluctuation might be a marker of reinnervation or else indicate another
mechanism of non-autonomic modulation. Bernardi et al studied the significance of the
spontaneous fluctuations in HRV in heart transplant recipients 34 . A brief review of
respiration-related and non respiration-related changes in HRV and the responses to
various physiological and pharmacological maneuvers are discussed in the following
sections.

5.4.1Respiration-related Changes in HRV
Spontaneous Respiratory Sinus Arrhythmia

The heart rate of the transplanted heart is not fixed, Even the first recordings after heart
transplantation show heart period fluctuations, though the extent amounts only about 14% of that observed in normal subjects. For at least the first year the only fluctuation
present is clearly related to respiration, and can be considered as a special type of
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respiratory sinus arrhythmia (RSA). However, the phase between the changes in the RR
interval and the phase of respiration differs from that observed in normal subjects. It was
found to be about 1.5 sec in normal subjects, but in transplanted patients it was
significantly shorter, in the range of 0.5 sec.

Changes in Frequency and Depth of Breathing
In normal subjects the RSA has a maximum variability around a respiration rate of 0.1 Hz
and decreases with increasing breathing frequency, but transplanted subjects increase
their RSA variability with increasing respiratory frequency. Also, while controls show
only a minor dependence of RSA on tidal volume, RSA power is much greater with
increasing tidal volume in transplanted subjects. Taken together, these results suggest that
it is the rate of change in ventilation that that determines the RSA in the denervated heart.

Changes in Heart Rate Induced by Valsalva maneuver
The valsalva maneuver acutely alters the intrathoracic pressure in a "square wave"
fashion. This maneuver is divided into four phases. Phase I, a transient increase in
systemic blood pressure with the onset of straining, reflects increased intrathoracic
pressure. Phase II, a gradual decrease in pulse pressure, and stroke volume due to a
decrease in venous return, is often referred to as the active phase of the valsalva
maneuver. During phase III (initial release of straining), the blood pressure transiently
decreases further as a result of abrupt decrease in intrathoracic pressure. This phase is
rapidly followed by phase IV, characterized by an overshoot of the systemic pressure
over baseline values. In normal subjects, a progressive tachycardia (increase in HR) and
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a sudden bradycardia (decrease in H

R

) are observed during the strain and release phases

of the valsalva maneuver, respectively. Minor or no changes are caused by this maneuver
in patients early after heart transplantation.

Changes in Respiratory Components During Physical Exercise
In normal subjects, physical exercise is thought to be responsible for a sudden withdrawal
of vagal activity and a progressive increase in sympathetic activity. As a consequence,
one expects and sees a rapid decrease in RSA at the beginning of exercise; on the other
hand, the increase in ventilation determines also an increase in respiratory-synchronous
changes in venous return, which should increase the changes in stretch imposed on the
right atrium, and increase RSA. In transplanted subjects, physical exercise actually
increases RSA. In transplanted subjects, physical exercise actually increases RSA; the
increase is directly correlated with that in ventilation, and inversely correlated with the
increase in heart rate: as a consequence, the maximum increase in RSA occurs at the
beginning of exercise. With progression of exercise, the slow increase in heart rate seems
to counteract part of the effect of the increase in ventilation, and the RSA declines toward
baseline levels.

Changes in Respiratory Components During Tilting
Tilting causes an absolute or relative decrease in vagal activity and it also causes a
reduction in central venous volume; but the respiratory variations in venous return are
unchanged or increased in the upright position. During head up tilt RSA is markedly
reduced in normal subjects and this effect is clearly due to autonomic changes.
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Conversely, in heart transplant subjects, RSA does not decrease, or in some subjects
increases, showing that the behavior of the RSA in these subjects follows that of venous
return rather than autonomic activity.

Changes in Respiratory Components During Neck Suction
Neck suction is a noninvasive technique, which selectively (i.e., without other effects
other than autonomic) stimulates the carotid arterial baroreceptors. A sudden suction to
the neck region normally causes a sudden bradycardia, due to increased vagal outflow to
the heart. This response was absent in heart-transplanted subjects. Sinusoidal neck
suction at a frequency similar to that of respiration was used to compare the effects of
pure autonomic stimulus (i.e., neck suction) with that of a mixed autonomic and
mechanical stimulus (i.e., respiration). In normal subjects both stimuli resulted in
oscillations in RR interval that could be detected by power spectral analysis. In heart
transplanted subjects, only respiration could change RR interval.

Changes in Respiratory Components After Parasympathetic Blockade
Although intravenous administration of atropine (at doses able to effectively block the
vagus) greatly reduce overall HRV, there remains a residual RSA of the same order of
magnitude as that observed in heart transplant subjects, in whom atropine has no effect,
Neck suction at near respiratory frequency is unable to generate high frequency
oscillations after atropine, while the respiratory fluctuation remains unchanged in both
normal and transplanted subjects.

5.4.1Non Respiration-related Changes in HRV
Spontaneous Fluctuations

A non-respiratory fluctuation in RR interval, particularly in the range of 0.1 Hz, can only
be due to autonomic activity, and in the case of heart transplantation this will imply
reinnervation. Such non-respiratory fluctuations were found in about half of the subjects
in this study who underwent heart transplantation at least 14 months before. The most
likely explanation for this is partial autonomic reinnervation, but although non-respiration
related LF is considered an acceptable marker of sympathetic activity, this observation is
alone not sufficient to decide whether this is due to sympathetic or vagal activity or both.

Effect of Tilt

In most long-term heart transplant subjects the LF components, evident in the supine
position, remained unchanged in absolute terms after tilting. This behavior is similar to
that of normal subjects; during tilting the LF remain unchanged in absolute terms, while
the respiration related fluctuations (HF) decrease, so that in absolute terms the LF
increase and the HF decrease.

Effect of Physical Exercise

As physical exercise increases sympathetic activity, an increase in LF could be seen in
normal subjects during moderate exercise. Furthermore, due to marked decrease in
overall RR interval variability, this increase is evident only in relative terms. LF
fluctuations not due to occasional slow breathings could be found only in a limited
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number of heart-transplanted subjects and only in subjects after at least two years from
transplantation.

Changes in LF Components During Neck Suction
While sinusoidal neck suction at near respiratory frequency was ineffective, stimulation
at 0.1 Hz significantly increased the LF in those transplanted subjects who exhibited
spontaneous LF at rest. In addition in a limited number of subjects who had no LF at rest,
0.1 Hz fluctuations could be induced by neck suction.

Changes Induced by Pharmacological Interventions
Amyl nitrite causes a sudden direct vasodilation, which elicits an immediate
reflex tachycardia in normal subjects, thought to be of sympathetic origin. In this study
only transplants with LF could increase their heart rate in response to the drug, further
suggesting a sympathetic origin of their LF.
The results of this study 34 are summarized in the tables 5.1 and 5.2. Analyses of
the manipulations, which affect the RR interval variability in heart transplant subjects,
indicate that the respiratory components largely reflect non-autonomic changes. Amongst
the various methods examined, sinusoidal neck suction appears optimal for noninvasive
demonstration of the presence and the progress of reinnervation, as it can give
information on both the sympathetic and vagal branches (by using different frequencies
of neck suction).
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Table 5.1Respiratory Fluctuations (HF) of RR interval in Normal Vs Heart Transplanted
Subjects
Normal subject
Present

Transplanted subject
Present but very small

Decreases above 0.1 Hz
Small increase
Tachy/bradycardia
Marked reduction

Increases
Big increase
—No effect
No effect or increases

Decreases
Decreases further
Increases

Increases
Remains high but drops
Decreases

Neck suction
-Impulsive
-Sinusoidal, HF

Bradycardia
HF oscillation

No effect
No effect

Atropine

Marked reduction

No effect

Stimulus
Spontaneous breathing
Voluntary breathing
-Frequency i
-Tidal volume T
Valsalva maneuver
Tilt
Physical exercise
-Beginning
-Peak
-Early recovery

Table 5.2 Non-respiratory Fluctuations (LF) of RR Interval in Normal Vs. Heart
Transplanted Subjects
Stimulus
Spontaneous breathing

Normal subject
Present.

Tilt
Physical exercise
-Beginning
Neck suction
Sinusoidal — LF
Atropine
-Alone
-With LF neck suction

No change in power

Transplanted subject
Present but small, after > 1
year, in ~ 50%
No change in power

Increases

Might increase

Increases LF oscillation

Increases LF oscillation

Marked drop but present
Does not block the increase
in LF

No change
Does not block the increase
in LF

Reduces LF (long term)
Unknown
Tachycardia

Reduces LF
Reduces the increase in LF
Tachycardia

Beta-Blockade
-Alone
-With LF neck suction
Amyl nitrite

CHAPTER 6

EVIDENCE FOR REINNERVATION OF THE HUMAN HEART

6.1 Introduction
The presence of cardiac reinnervation after cardiac transplantation in humans has been
widely debated based on the application of differing methods for the assessment of
neuronal function. Some of these techniques have been rather indirect; consequently, the
time course and extent of cardiac reinnervation remains uncertain. In some postmortem
studies of human cardiac allografts, nerves and ganglion cells have been demonstrated
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Histological studies performed in canine transplant models and dogs have demonstrated
considerable reinnervation within the first year after surgery 59 . Wharton et al examined
myocardial tissue obtained at surgery from patients undergoing retransplantation. In their
study using immunohistochernical techniques, viable intrinsic nerves were demonstrated,
but they were unable to demonstrate the presence of extrinsic nerves in the majority of
tissues examined 72 . Studies that provide evidence for reinnervation will be discussed in
the following paragraphs.
Tio et al conducted a study to find the evidence for differential sympathetic and
parasympathetic reinnervation after orthotopic heart transplantation in humans. Heart rate
variability analysis was used to investigate signs of reinnervation. Both sympathetic and
parasympathetic activity was demonstrated by spectrum analysis of HRV. All HRV
parameters were found to be lower in heart transplantation. Another important finding of
this study was that heart rate variations were less when the donor was older, and higher in
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case of a longer time after transplantation. A study by Koskinen et al also found that heart
rate variability increases with post-transplantation time 67 .
To evaluate the presence of reinnervation, Bernardi et al investigated the
spontaneous variability in R-R interval, supine and after passive tilting in 23 heart
transplant recipients and in 25 normotensive control subjects by autoregressive spectral
analysis of low- and high- frequency spontaneous fluctuations in R-R interval and
respiration 45 . Detectable LF oscillations, unrelated to respiration, were present in 13/23
heart transplant recipients, particularly in those who were transplanted at least 20 months
earlier (11/14). The natural logarithm of the power of LF fluctuations was markedly
lower than in control subjects. The LF but not the HF correlated with time since
transplantation. The conclusion of this study was that signs of functional (reflex)
reinnervation could be found in most heart transplant recipients.
To find the electrophysiological evidence of reinnervation of the orthotopic
transplanted human heart Wesche et al studied the beat-by-beat heart rate (HR) changes
during exercise in two young and fit heart-transplanted humans at different time intervals
following transplantation 44 . Upon the start of the exercise, a slow gradual increase in HR
was seen during the early experiments after the transplantation, whereas an immediate
rapid increase in HR was observed during the later experiments, which suggests
reinnervation. From standard ECGs obtained 32 months after transplantation, two P
waves at somewhat different rates could be identified in both subjects, probably arising
from donor and recipient sinoatrial nodes, respectively. The two P wave rate changes
during and following exercise were very similar. The conclusion of this study was that
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these changes in the HR pattern and ECG must be due to reinnervation of the donor
hearts, most likely by parasympathetic cardiac fibers.

6.2 Sympathetic Reinnervation
In patients studied within 5 months following orthotopic cardiac transplantation,
intravenous tyramine administration, which ordinarily causes release of norepinephrine
from sympathetic nerve endings, produced a significant increase in systolic blood
pressure but no change in HR and no intracardiac release of norepinephrine (Wilson et al,
1991). In transplant patients studied at 12 or more months following surgery, however,
tyramine did stimulate a small increase in HR and a significant intracardiac release of NE
and a blood pressure response. These findings provide evidence of sympathetic
reinnervation in patients late after cardiac transplantation. When the same group of
investigators compared heart transplant patients less than and more than 1 year following
surgery, they found similar changes over time in the HR response to sinoatrial artery
tyramine infusion and in norepinephrine release into the left main coronary artery. Thus,
reinnervation is defined as a measure of cardiac norepinephrine release after
intracoronary tyramine injection. Burke et al demonstrated evidence for functional
sympathetic reinnervation of left ventricle and coronary arteries by tyramine injection.
The implication of this study was that stimulation by tyramine of regenerating
sympathetic neurons in transplanted hearts can affect both left ventricular contractility
and vasomotor tone in a manner similar to that seen in healthy hearts.
Schwaiger et al (1991) reported evidence suggesting regional sympathetic
reinnervation among transplant recipients studied more than 2 years after surgery but not
among patients studied less than 1 year following surgery. Additional evidence for late
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(more than 2 years after transplantation) sympathetic reinnervation of the heart derives
from tyramine stimulation studies in two patients with angina pectoris 3 years after
transplantation (Stark, McGinn, & Wilson, 1991) and studies of cardiac norepinephrine
spillover and HR in a rest and exercise paradigm57 (Kaye et al., 1993).
Cardiac norepinephrine spillover = RNEcs-NEA)-F(NEA*NEEx)] * CSPF
Where NE A and NEcs are arterial and coronary sinus plasma concentrations of
norepinephrine, NE Ex is the fractional extraction of tracer norepinephrine across the
heart, and CSPF is the coronary sinus blood flow.
Doering et a1 73 evaluated cardiac reinnervation early and late after heart
transplantation. Handgrip and deep breathing tests, passive 80 degrees head-up tilt, and
heart rate (HR) responsiveness of 33 transplant recipients (n = 16 at < 5 months and n =
17 at > 1 year after transplant) were compared with those of 16 age- and sex-matched
control participants. The results of this study suggest that sympathetic reinnervation
occurs late (>1 year) after transplantation. The results of this study also suggest that the
time elapsed since transplant should be considered when caring for transplant recipients.
Other studies evaluating heart period variability following heart transplantation
generally indicate that all measures of variability are dramatically and persistently
reduced by cardiac transplantation (Bernardi et al., 1989, Sands et al., 1989, Shapiro et
al., 1996). By studying the immediate cardiovascular responses upon active transition
from the supine to standing posture in the early and late months after heart
transplantation, Rudas et al demonstrated that the development of heart rate
responsiveness is compatible with sympathetic reinnervation 54 , 55 Reinnervation has also
.
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been confirmed using PET studies 46 ' 47 (Demarco et al., 1995, Estorch et al., 1999) and
SPECT48 , 49 (Parry et al 1997, Toba et al., 1998, Bengel et al., 1999).

6.2.1 Functional Vs. Structural Reinnervation
The functional evidence for the recurrence of system dynamics late after transplantation
addresses the issue of its structural representation. In the intact heart control of heart rate
is governed by the extrinsic nervous system, i.e., branches of the central autonomic
nervous system, and the intrinsic cardiac nervous system, located in the fat pads near the
base of the heart and containing efferent post-ganglionic sympathetic and
parasympathetic neurons, local circuit inter neurons, and afferent neurons. The intrinsic
system, even after surgical extrinsic decentralization, has been demonstrated to retain
some capacity to modulate the heart by administration of substances like isoprotenol,
tyramine or nicotine, which stimulate cardiac norepinephrine release (Murphy et al.,
1994). Other lines of pharmacological and physiological evidence suggest that this
intrinsic system has functions very similar to those that occur with the neural
superstructure intact (Armour et al., 1994; Huang et al., 1993; Murphy et al., 1994). Thus,
functional occurrence of heart rate control are due to reinnervation of the transplanted
allograft by the extrinsic nervous system, but there is also a possibility that the posttransplant recovery of heart rate variability may be due to new organizations and
reorganizations of the viable intrinsic cardiac neurons.
Fagard et al conducted a study to find signs of functional reinnervation. Shortterm heart rate and blood pressure variability were assessed in 62 patients, studied within
1 month, at 1, at 2 or at 3-5 years after transplantation and in 13 healthy control
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subjects 63 . Means and total variances were calculated and the powers of the LF and of HF
components were lower in the transplanted patients than in the controls. The total
variance and the LF and HF components were lower in the transplanted patients than in
the controls. The total variance and the LF and HF powers differed significantly among
the groups of transplanted patients and intergroup comparison showed significantly
higher values in patients 3-5 years after transplantation than in those studied within 1
month. The results of this study suggest that partial functional reinnervation of the sinus
node occurs after heart transplantation.

6.2.2 Regional Differences Sympathetic Reinnnervation After HTX
In the majority of humans

1 year after cardiac transplantation, cardiac norepinephrine

(NE) stores reappear, suggesting late sympathetic reinnervation. To determine whether
there are regional differences in reinnervation, Wilson et al studied markers of
sympathetic reinnervation of the sinus node (SN) and left ventricle (LV) in five early
transplant recipients (<= 4 months after cardiac transplantation), 45 late transplant
recipients 1 year after cardiac transplantation), and 7 normally innervated control
patients 49 . SN reinnervation was defined as an increase in heart rate by more than five
beats per minute after injection of tyramine into the artery supplying the SN. LV
reinnervation was defined as a measurable LV NE release after left main coronary
injection of 8 μg/kg tyramine. In 13 patients with previously known LV reinnervation,
regional LV reinnervation was assessed by NE release after sub selective injection of
tyramine (4 μg/kg) into the proximal left anterior descending and circumflex arteries.
Five of five patients <= 4 months after cardiac transplantation had no change in heart rate
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and no LV NE release, confirming early, total denervation. In contrast, 1 year after
cardiac transplantation, tyramine caused a heart rate increase (8 to 49 beats per minute) in
32 of 45 patients and LV NE release in 33 of 45. Although LV NE release was correlated
with the change in heart rate in late cardiac transplantation recipients, 8 of 45 had only
heart rate response, 9 had only LV NE release, and 4 had neither. In late cardiac
transplantation recipients with LV reinnervation, tyramine caused NE release from both
the anterior descending and circumflex perfusion fields in 10 of 14, but one of 14 patients
released NE only after circumflex tyramine and three of 14 only after anterior descending
tyramine stimulation. Tyramine caused a marked heart rate increase and LV NE release
in all control patients.
Thus this study demonstrated that sympathetic reinnneravtion after cardiac
transplantation is regionally heterogeneous. Reinnervation of the sinus node did not
imply necessarily that the left ventricle is reinnervated and the reverse, although there
was a weak relation between left ventricular and sinus node reinnervation. Similarly,
reinnervation within the left ventricle occurred with approximately equal overall
frequency in the perfusion fields of the circumflex and left anterior descending arteries,
but in individual patients, norepinephrine release was found in the posterior or anterior
walls separately or together. The time course of sinus node reinnervation was similar to
that of left ventricular reinnervation, becoming detectable about 1 year after
transplantation and increasing in magnitude thereafter.
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6.3 Sympathetic Reinnervation and Heart Rate Variability
Halpert et al evaluated HRV after cardiac transplantation in an attempt to test if
reinnervation occurred in the post-transplant period 65 . HRV was measured using 24-hour
Holter recordings performed on 37 ambulant patients 1 to 122 months after cardiac
transplantation. All patients were free of histological rejection and were taking no
medication likely to influence HRV. Time and frequency domain were analyzed. HRV
was found to increase with time after the transplant. Compared with patients in the early
post-transplant period, patients >36 months after transplant had lower 24-hour heart rates,
an increased average of all 5-minute SD's of NN intervals and higher low- and highfrequency power. Ten of the 27 patients >3 years after transplantation had evidence of
functional cardiac reinnervation, The conclusion of this study was that patients late after
transplantation have HRV evidence for an increase in sympathetic control of heart.
Heart rate variability (HRV) is reduced immediately after heart transplantation,
but is found to increase with time suggesting that reinnervation occurs. Lord et al
conducted a study to examine the relationship between sympathetic and parasympathetic
reinnervation of the heart, and the various components of HRV using the cardiac
transplant recipient as a model. Twenty-four cardiac transplant recipients at the time of
routine surveillance coronary angiography two or more years after cardiac
transplantation, and 10 controls with normal coronary arteries were used for the study.
Sympathetic effector function at the sinus node was assessed by measuring the
fall in RR interval for two minutes after injection of tyramine to the artery supplying the
sinus node. HRV was measured from three-minute RR interval sequences at rest, during
metronomic respiration, and before and after injection of tyramine. Example patterns of
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response to tyramine are shown in figure 6.1 for a control subject, a transplant recipient
with no evidence of reinnervation, and a transplant recipient with evidence of
reinnervation. Figure 6.1 also shows examples of spectra derived from the resting RR
interval sequences in the same subjects. Although there is a dramatic response to
tyramine in the transplant recipient with evidence of reinnervation, this is reflected only
in an attenuated LF peak, and the continuing absence of an HF peak. Both LF and HF
components of the spectrum were significantly lower in transplant recipients compared
with controls.
The results of this study showed that the logarithm of the low frequency
component of HRV during metronomic respiration was linearly related to the logarithm
of the change in cycle length after injection of tyramine. Absolute units more accurately
reflected sympathetic effector function than did normalized units or the ratio of low
frequency to high frequency. Atropine did not affect HRV in transplant recipients. The
conclusion of this study was that the low frequency component of HRV is directly related
to sympathetic reinnervation of the sinus node.
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Figure 6.1 Comparison of results from a control subject (upper panel), a transplant
recipient in whom there was no evidence of reinnervation (middle panel), and a transplant
recipient in whom there was evidence of sympathetic reinnervation (lower panel). The
cardiac cycle length response to intracoronary injection of tyramine is shown on the left,
and the spectrum from a resting RR interval sequence on the right. (Lord S, W., et al.,
"Sympathetic reinnervation and heart rate variability after cardiac transplantation,"
Heart, 1997.)
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6.4 Exercise Capacity and Reinnervation After Heart Transplantation

Although successful cardiac transplantation improves the patient's quality of life, the
cardiovascular responses to exercise remain abnormal for long periods, and the exercise
capacity in terms of maximum power output or maximum oxygen uptake is reduced by
about 25-50% both in adults and in children. The presence or absence of cardiac
reinnervation may therefore be pertinent to the improvement in exercise capacity late
after cardiac transplantation. The results from a study by Meyer et al have provided
functional evidence for the reemergence of the "dimensionality" of cardiac control, but
the time course for recovery to normal appears to be on the order of about 10 years,
Many studies have shown that different components of the heart interact better
with time after transplantation, Thus, cardiac mechanics is related to time after surgery.
Lord et al conducted a study to investigate the relation between sympathetic efferent
reinnervation and exercise response after cardiac transplantation 51 . 25 long-term cardiac
transplant recipients and 11 normal controls were used for the study. Intracoronary
tyramine was given to the transplant recipients and the percent heart rate change was
measured. Exercise tests were performed in patients and controls according to the
chronotropic assessment exercise protocol 74 , and the percent heart rate reserve (HRR)
measured at peak exercise and 6 minutes afterwards to estimate the recovery rate. The
following formulas were used for the purpose.
HRR = (HR at peak exercise — resting HR)/(Age predicted maximum HR — resting HR)
6 min recovery = (HR at peak exercise — HR 6 min later)/(Age predicted maximum HR —
resting HR)
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Mean chronotropic response to exercise workload, and response to tyramine were
compared using statistical methods

(t

test). Relation between response to tyramine and

exercise variables were quantified using linear regression analysis. The results of the
study demonstrated that chronotropic competence and response to intracoronary tyramine
vary widely among transplant recipients at more than two years after transplantation.
While both techniques measure the changing physiological responses after
transplantation, the fact that there is a significant correlation between them suggests that
they are both related to sympathetic efferent sinus node reinnervation. In those patients in
whom sinus node reinnervation was demonstrated using tyramine, exercise time and total
workload were increased as compared to heart transplant patients who had lesser signs of
reinnervation. HRR and 6 min recovery were also high in patients with suggested
reinnervation by increase in HR after tyramine administration, In normal controls the
values for exercise time, HRR, 6 min recovery, and total workload were higher than that
for transplant recipients. Thus, this study demonstrates that sympathetic reinnervation has
clinical consequences.
To assess the development of HR responses to exercise, Rudas et al studied HR
changes in response to orthostasis and treadmill exercise in 52 orthotopic cardiac
transplant recipients 53 . HR response to standing in normal subjects was compared with
HR in transplant recipients the results of which are shown in figure 6.2 (RR interval (ms)
Vs. cardiac cycle). In early heart transplant patients (group 1) there was no significant
change in heart rate for up to 100 cycles after standing. Patients 1-2 yr after
transplantation (group 2) showed an increase in HR by the sixteenth to twentieth cardiac
cycle after standing. Late transplant patients (group 3) were found to have significant
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shortening of the RR interval by the fifth cardiac cycle after standing. HR responses on
standing, during early exercise, and after exercise are shown in figure 6.3. Marked
differences in HR recovery of the three groups where seen early after exercise. HR
deceleration 1 minute after exercise was also related to the time after transplantation. The
results of this study indicate development of functional reinnervation after orthotopic
heart transplantation. The phenomenon of early acceleration of the HR after orthostasis
(standing up from a supine position) and rapid deceleration after exercise in transplant
recipients implies a local cardiac mechanism rather than response to circulating
catechol amines.
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Figure 6.2 Changes in RR interval after standing in normal subjects and heart transplant
recipients at varying times after heart transplantation. Different scale in RR interval is
used for normal (right) and transplant (left) subjects. (Rudas L., et al., "Evolution of heart
rate responsiveness after orthotopic cardiac transplantation," The American Journal of
Cardiology, 1991.)

Figure 6.3 HR responses on standing (left), during early exercise (middle), and after
exercise (right) in heart transplant recipients at varying times after heart transplantation.
(Rudas L., et al., "Evolution of heart rate responsiveness after orthotopic cardiac
transplantation," The American Journa/ of Cardiology, 1991.)
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6.5 Detecting Acute Graft Rejection in Patients After Orthotopic Heart
Transplantation: Analysis of HRV in the Frequency Domain
Acute transplant rejection (AR) is a major complication after heart transplantation. To
treat patients with rejection, early detection is necessary before fatal heart dysfunction.
Because of its invasive aspect, endomyocardial biopsy is limited with respect to its
frequency and complication rate. Frey et al investigated the potential of HRV as a noninvasive tool for continuous follow-up of patients who have undergone heart
transplantation to detect AR at an early stage. In an attempt to test this hypothesis, Sands
et al. have demonstrated an increased HRV during AR. However, no respiratory sinus
arrhythmia could be observed. In contrast to that, Zbilut et al. have shown respiration
induced periodicity in HRV and report a decrease in HRV during AR when approaching
the respiration frequency. The study of Frey et al., which will be described in the
following paragraphs, was designed to establish which HRV-frequency components
reliably detect AR and to gain an insight into possible underlying mechanisms of HRV
changes during AR.
After endomyocardial biopsy in 117 heart transplant recipients (age 49±13 years,
time after transplantation 6 to 48 months), electrocardiography results were recorded with
the patient in a supine position at a controlled respiration rate (0.1 and 0.25 Hz) over 10
minutes. To minimize the effects of medication, only patients who underwent HTX
greater than 6 months were enrolled. Patients with an artificial pacemaker or severe
arrhythmia were excluded. Following these criteria, a total of 156 electrocardiographic
recordings for both controlled respiration rates were retained. The spectra of RR intervals
were calculated, and different spectral components were evaluated: LF, HF, LF+HF,
LF+HF-RP (RP=respiratory peak), and the total power.
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On the basis of the 156 electrocardiograms analyzed and endomyocardial biopsy
reports, three groups of patients were defined: Group I-patients without rejection (ARO,
n=73), group II-patients with mild rejection (AR 1 a, n=51), and group III-patients with
severe rejection (AR lb to AR4, n=32). To investigate the performance of HRV in
discriminating between groups of patients with respect to AR, statistical measures such as
sensitivity and specificity were used. For each frequency domain parameter, sensitivity
and specificity curves as function of varying threshold value were calculated. All the
frequency domain parameters except HF were significantly higher in patients with severe
AR than in patients without AR. The comparison between groups I and II and groups H
and TIT showed a significant difference only in LF.
To compare the changes of HRV during AR with mechanically induced changes
during a controlled respiration frequency, the electrocardiograms monitored at the low
respiration rate (0.1 Hz) were analyzed. During this slow respiration rate, LF was
significantly higher in patients with severe AR than without AR. For heart transplant
recipient groups I and II, LF was compared at respiratory rates of 0.1 and 0.25 Hz. As
expected a significant decrease of LF was observed in patients with no AR when shifting
the respiratory rate from 0.1 to 0.25 Hz. However, in heart transplant recipients with
severe AR the decrease of LF when increasing the respiratory rate was not statistically
significant.
Thus the results of this study suggest that power spectral analysis of HRV is a
promising tool for the quantification of acute graft rejection in patients after heart
transplantation. With this simple and noninvasive technique, it was shown that the power
spectrum density of HRV increases during AR and thus mild-to-severe acute graft
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rejection could be detected (figure 6.4). Compared to heart transplant recipients with no
evidence of AR, a significant increase in HRV was observed in those showing severe AR.
On the basis of this study, the increase of HRV power is due to an increase in signal noise
rather than in the amplitude of periodic components. The evolution of different
parameters in the frequency domain of HRV with respect to AR was analyzed. The
calculation of sensitivity-specificity relation showed that the most reliable parameter in
the frequency domain for AR detection is LF+HF-RP.

Figure 6.4 HRV power spectral density for same heart transplant recipient during no AR
episode (dashed line) and during AR episode (solid line). (Frey A.W., et al., "Detecting
acute graft rejection in patients after orthotopic heart transplantation," Journal of Heart
and Lung Transplant, 1998.)

The study conducted by Uberfuhr et al to estimate the predictive power of HRV in
detecting AR yielded similar results 63 , The conclusion of this study was that during
rejection the variability increases significantly both in the time domain and in the
frequency domain. This was attributed to an irregular increase of the amplitude of the
beat-to-beat variability of QRS distances.
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6.6 Parasympathetic Reinnervation
The presence of parasympathetic reinnervation is still controversial and no unequivocal
evidence has been reported with conventional transplantation. Many authors have not
observed any sign of parasympathetic reinnervation. Arrowood et al conducted a study to
determine if reinnervation of chemosensitive endings subserved by cardiac vagal
afferents (endings connected to the central nervous system by fibers running alongside
vagal fibers) occurs after human orthotopic heart transplantation 66 . Two cardiac groups
were studied: an "early" group (n=18, <24 months after transplant) and a "late" group
(n=18, >43 months after transplant); these groups were compared with a control group
with intact innervation (n=18). The reflex response of the recipient sinus node (RSN) in
the remnant right atrium, which remains innervated after transplantation, was observed
during selective right coronary artery and left coronary artery injection of a radiographic
contrast, to stimulate ventricular chemosensory nerve endings. A decrease in the rate of
RSN was expected if reinnervation of chemosensory endings had occurred and the
afferent limb of the cardiac depressor reflex was intact. With injection, the RSN rate of
both transplant groups did not decrease but increased compared with the expected
decrease in control patients. The results obtained from this study suggest that
reinnervation of ventricular chemosensory endings subserved by vagal afferents in
cardiac transplant patients does not occur up to 74 months after transplantation.
Raczak et al conducted a study to test the presence of parasympathetic
reinnervation by assessing the baroreflex sensitivity in 30 patients 1-24 months after
transplantation 69 . The results of this study suggest that vagal efferent reinnervation of the
donor heart does not occur up to 24 months in patients who underwent heart
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transplantation by the Lower and Shumway method. The study also suggested that
analysis of baroreceptor reflexes is a more specific method in the examination of cardiac
parasympathetic reinnervation.
Fitzpatrick et al (1993) found evidence for vagal reinnervation in transplant
recipients. Among 10 patients studied at a mean post surgical interval of 22±12 months, 7
had a vasovagal response to tilt testing and 3 had slowing of the graft heart (which can be
due to parasympathetic activity). Some studies assessing heart period variability have
demonstrated a trend toward increasing HF power over time (Fallen et al., 1988, Kaye et
al., 1993) and correlation with exercise studies has led to the suggestion that
parasympathetic reinnervation begins to have a functional effect only two or more years
following heart transplantation (Kaye et al., 1993).
To find the signs of vagal reinnervation, Uberfuhr et al investigated the spectral
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analysis of HRV in 13 patients after heart transplantation . 18 healthy volunteers were
selected as control group. For each patient two recordings were performed which took
part 14±5 months and 42±8 months respectively after heart transplantation. ECG was
recorded simultaneously for 5 min in supine position during controlled respiratory rate of
12 or 15 cycles/min. No graft rejection has been detected in the endomyocardial biopsy
performed right after the recordings. Power spectral densities were calculated for the
beat-to-beat time series of RR intervals.
The figure 6.5 illustrates the power spectral densities from a patient at its first (16
months) and second (30 months) recording and visualizes the increase of power spectral
densities in the low and high frequency band. The differences of the values of the power
spectral densities between transplanted patients and control subjects are striking, in
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particular, in the low frequency band. A significant increase of LF and HF power during
a mean period of 28 months could be found.
The conclusion of this study was that an increase of HF band suggests
parasympathetic reinnervation. This study also confirms that the LF band increases 4
years after transplantation, suggesting a possible sympathetic reinnervation of the heart.

Figure 6.5 Top: tachogram and power spectrum of a patient 16 months after HTX;
Bottom: recordings of the same patient 30 months after HTX. (Uberfuhr et al, "Signs of
vagal reinnervation 4 years after transplantation in spectra of heart rate variability,"
European Journal of Cardiothoracic Surgery, 1997.)
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6.7 Influence of Type of Surgery on the Occurrence of Parasympathetic
Reinnervation After Cardiac Transplantation
Standard surgical techniques leave most of the recipient atria intact and most of the
parasympathetic axons also remain intact and thus might not be stimulated to regenerate.
Conversely, the bicaval technique (by which the whole recipient heart including the
entire atrial junctions of both superior and inferior venaecavae are removed (orthotopic
transplantation) and substituted with equivalent components of the donor heart) cuts
100% of both sympathetic and parasympathetic fibers and can therefore stimulate both
branches to regenerate 70 .
To investigate the influence of type of surgery on the occurrence of
parasympathetic reinnervation after cardiac transplantation Bernardi et al studied 89
orthotopic heart transplant recipients, 10 with bicaval and 79 with standard surgery 70 .
Changes in the R-R interval power spectrum induced by sinusoidal modulation of arterial
baroreceptors by neck suction at different frequencies were used to detect both
sympathetic and parasympathetic reinnervation. In 24 subjects (17 standard and 7
bicaval), the protocol was repeated 6 and 11 months after transplantation. Neck suction at
0.2 Hz produced a component at 0.2 Hz in the RR-interval spectrum not due to
respiration (fixed at 0.25 Hz), which suggested parasympathetic reinnervation, in 4 of 10
bicaval but in only 2 of 79 standard transplant subjects (whose recipient atria underwent
>50% resection to remove scars of previous interventions). In only 1 (bicaval) transplant
subject was parasympathetic reinnervation present 6 months after transplantation
(confirmed 3 months later); in 4 subjects, it was absent at 6 months but appeared after 11
months after transplantation. Atropine abolished the HF response to fast (0.02 Hz) and
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reduced that to slow stimulation, confirming the presence of parasympathetic
reinnervation (4 subjects).
The present study confirms that a rudimentary sympathetic reinnervation is
relatively frequent, occurring in 50% of the heart transplant recipients. Thus, whereas,
after standard surgery, only sympathetic reinnervation is common, after bicaval surgery
the frequencies of parasympathetic and sympathetic reinnervation are similar (4 of 10
versus 6 of 10, respectively, 9 months after transplantation). All this indicates that the
surgical technique plays a major role in the probability of subsequent development of
parasympathetic reinnervation,
The distributions of neural endings in the two surgical techniques are shown in
figure 6.6.

Figure 6.6 Schematic of different distribution of neural endings and possibility of
reinnervation in bicaval vs. traditional surgery (Bernardi et al., "Influence of type of
surgery on the occurrence of parasympathetic reinnervation after cardiac transplantation,"
Circulation, 1998.)
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6.8 Relative Frequency of Functional Sympathetic and Parasympathetic
Reinnervation After Heart Transplantation
Tio et al performed a study to investigate the sympathetic and parasympathetic
reinnervations and the results of the study showed that parasympathetic reinnervation
could occur with or without the signs of sympathetic reinnervation; sympathetic
reinnervation without parasympathetic reinnervation was not found.
Brunner-La Rocca et at conducted a study to determine the relative frequency of
sympathetic and parasympathetic reinnervation 71 . The study subjects comprised 65
patients 3 to 110 months after undergoing orthotopic heart transplantation and 16 healthy
volunteers. At the time of the study, patients were free from moderate or severe graft
rejections, had no features of heart failure, and were in a stable sinus rhythm. Control
subjects were free from heart medication and had no history, symptoms, or signs of
cardiovascular disease. The heart rate response to various maneuvers (standing up,
handgrip exercise, phase 2 of Valsalva maneuver for sympathetic function, carotid sinus
massage, phase 4 of Valsalva maneuver, and atropine for parasympathetic function) was
examined in the study subjects and in the control subjects. Reinnervation was defined as
either one normal (>50% of control group) and at least one partial (>33% of control
group) heart rate response or partial responses in all three tests of the respective part of
the autonomic nervous system.
Changes of heart rate to the different maneuvers were overall markedly
diminished in patients after heart transplantation as compared with healthy volunteers.
However, a considerable number of patients had a partial or a normal heart rate response.
Thirty-five (54%) patients had sympathetic reinnervation, but only 16 (25%) had
parasympathetic reinnneravtion; earliest reinnervation was found 11 months after
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transplantation, and 41 but one patient with parasympathetic reinnneravtion also had
sympathetic reinnneration. The frequency and extent of parasympathetic reinnneravtion,
late after transplantation (>5 years) were markedly lower as compared with sympathetic
reinnneravtion (74% Vs 30%). As the type of surgical technique (bicaval or standard)
used for heart transplantation in this study was not clearly indicated in the literature, this
difference in reinnervation can be attributed to the type of surgery 70 .

CHAPTER 7

CONCLUSIONS AND FUTURE STUDIES

In recent years, analysis of the HRV signal in time and frequency domain has revealed
important physiologic and prognostic information. Extensive literature review of articles
that describe reinnervation and HRV after heart transplantation was performed, the
conclusions of which are summarized in the following paragraphs.
From the survival statistics obtained from ISHLT and UNOS databases it is
evident that heart transplantation has emerged as a successful treatment of end stage heart
disease. The major continuing limitation to the volume of heart transplantation has been
that of donor availability. Because left ventricular assist devices (LVAD) could be made
readily available without the need for a waiting list, they might compete well with the
strategy of heart transplantation. Although further study is required to overcome the
limitations of LVADs, the recent advances made in this field are promising.
Heart rate variability was found to be substantially blunted early after heart
transplantation. Long-term follow up studies after heart transplantation, which were
reviewed in the course of this study, have shown that HRV improves with time after
transplantation. This can be attributed to the reinnervation after heart transplantation.
Thus, HRV is an efficient tool in measuring the extent of reinnervation.
Some of the studies that were reviewed in the course of this project are given in
table 7.1. HRV was the tool used in most of the studies.
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Table 7.1 A Review of Methods and Conclusions of Various Studies on Patients After

Heart Transplantation
Authors
Rudas et al, 1991

No: of
patients
52

Technique Used

Conclusion

HR responses to treadmill
exercise
HR responses to exercise +
Neurochemical studies

Functional
reinnervation
Restoration of cardiac
sympathetic nerve
function
HRV can predict
extend of recovery
Reinnervation
Reinnervation
Reinnervation
No functional
reinnervation occurs
upto 1 year after heart
transplantation
Sympathetic
reinnervation
Reinnervation
increases with post
transplantation time
Reinnervation
Reinnervation
Parasympathetic
reinnervation
Reinnervation
Reinnervation
Reinnervation is
heterogeneous

Kaye et al, 1992

15

Mortara et al, 1994

30

HRV

Bernardi et al, 1994
Burke et al, 1994
Fagard et al, 1995
Shapiro et al, 1996

26
56
62
20

HRV
Tyramine injection
HRV
Heart rate reactivity + Heart
period variability

Lord et al, 1996

25

HRV+ Tyramine injection

Koskinen et al, 1996

38

HRV

Halpert et al, 1996
Lord et al, 1997
Uberfuhr et al, 1997

38
24
13

HRV
HRV + Tyramine injection
HRV

Tio et al, 1997
Estorch et al, 1998
Bengal et al, 1999

16
31
30

HRV
SPECT
PET

The main conclusion of this research was that sympathetic reinnervation of the
transplanted human heart can occur > 1 year after transplantation. Reinnervation was
found to increase with time after heart transplantation and was seen more frequently 2
years post-transplantation. Also, complete reinnervation of the transplanted heart was not
found to occur even up to 12 years post-transplantation, Reinnervation was found to be
regionally heterogeneous. The findings of this study also suggested that reinnervation is
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less likely to occur in patients with a pretransplantation diagnosis of idiopathic
cardiomyopathy than in those with other etiologies of congestive heart failure. Studies
have shown that vast majority of graft rejection episodes, which is one of the major
complications after heart transplantation, occur before cardiac reinnervation. So HRV
analysis can be applied in assessing the prognosis after heart transplantation.
Exercise response of the transplanted heart was found to improve with
reinnervation. It was found that sympathetic reinnervation enables an increased peak
oxygen uptake, which means that reinnervation precedes functional recovery. Hence,
reinnervation can be used a promising measure of the cardiovascular status.
The type of surgical technique employed in the heart transplant procedure was
found to influence parasympathetic reinnervation. Most of the studies suggested that the
extent of parasympathetic reinnnervation, late after transplantation (>5 years) were
markedly lower as compared with sympathetic reinnnervation (74% Vs 30%). Also, a
higher donor age was found to reduce signs of reinnervation.
Despite the fact that HRV has been applied in a broad spectrum of cardiovascular
diseases, general agreement has been reached so far only in two clinical conditions: 1)
Impaired HRV can be used alone or in combination with other factors to predict risk of
arrhythmic events after acute myocardial infarction, and 2) decrease in HRV is a
successful clinical marker of evolving diabetic neuropathy. Recently, its role in the
evaluation and management of heart failure has also been recognized. Although several
earlier studies have reported on the clinical and prognostic value of heart rate variability
analysis in the cardiovascular assessment of patients after heart transplantation, this
technique has not been incorporated into clinical practice. The determination of exact
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sensitivity, specificity, and predictive value of HRV still requires further investigation
before standards can be set for applying this technique in finding the reinnervation after
heart transplantation. The measurement of HRV appears to be a well-established research
tool and is useful in the assessment of the function of central and peripheral modulators
involved in the control of the heart's beat-to-beat variability. Its clinical applicability still
remains limited because of the complex methodology and lack of standardization.
Large population studies with follow-up are needed to establish normal HRV
standards for various age and sex subsets. If standardization is followed, HRV has
considerable potential to assess reinnervation after HTX. Also, HRV analysis could be
used as a tool to evaluate the chances of survival in patients HTX. Follow-up studies on a
large group of patients are necessary to confirm the conclusions of this research.
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